



US008951737B2

**(12) United States Patent  
Bander****(10) Patent No.: US 8,951,737 B2**  
**(45) Date of Patent: \*Feb. 10, 2015****(54) TREATMENT AND DIAGNOSIS OF CANCER****(75) Inventor: Neil H. Bander**, Chappaqua, NY (US)**(73) Assignee: Cornell Research Foundation, Inc.**,  
New York, NY (US)**(\*) Notice:** Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 72 days.

This patent is subject to a terminal disclaimer.

**(21) Appl. No.: 11/939,422****(22) Filed: Nov. 13, 2007****(65) Prior Publication Data**

US 2009/0238755 A1 Sep. 24, 2009

**Related U.S. Application Data****(60)** Continuation of application No. 11/481,344, filed on Jul. 5, 2006, now abandoned, which is a continuation of application No. 09/929,546, filed on Aug. 13, 2001, now Pat. No. 7,163,680, which is a continuation of application No. 09/357,708, filed on Jul. 20, 1999, now Pat. No. 6,770,450, which is a division of application No. 08/895,914, filed on Jul. 17, 1997, now Pat. No. 6,136,311, which is a continuation-in-part of application No. 08/838,682, filed on Apr. 9, 1997, now Pat. No. 6,107,090.**(60)** Provisional application No. 60/016,976, filed on May 6, 1996, provisional application No. 60/022,125, filed on Jul. 18, 1996.**(51) Int. Cl.****G01N 33/53** (2006.01)  
**G01N 33/574** (2006.01)  
**A61K 39/395** (2006.01)  
**A61K 47/48** (2006.01)  
**B82Y 5/00** (2011.01)  
**C07K 16/30** (2006.01)  
**A61K 39/00** (2006.01)**(52) U.S. Cl.**CPC ..... **A61K 47/48638** (2013.01); **A61K 47/48761** (2013.01); **A61K 2039/505** (2013.01); **B82Y 5/00** (2013.01); **C07K 16/3069** (2013.01); **C07K 2317/77** (2013.01); **G01N 33/57434** (2013.01); **G01N 2333/705** (2013.01)  
USPC ..... **435/7.1**; 435/7.23; 424/130.1; 424/141.1; 424/155.1; 424/156.1**(58) Field of Classification Search**None  
See application file for complete search history.**(56) References Cited**

## U.S. PATENT DOCUMENTS

4,454,106 A 6/1984 Gansow et al.  
4,472,509 A 9/1984 Gansow et al.  
4,814,275 A 3/1989 Durda et al.  
4,855,353 A 8/1989 Kurami et al.4,863,851 A 9/1989 McEwan et al.  
4,863,854 A 9/1989 Mattes et al.  
4,885,363 A 12/1989 Tweedle et al.  
4,892,824 A 1/1990 Skaletsky  
4,943,525 A 7/1990 Dawson  
5,001,225 A \* 3/1991 Taylor ..... 530/388.6  
5,013,645 A 5/1991 Kim  
5,053,503 A 10/1991 Dean et al.  
5,057,302 A 10/1991 Johnson et al.  
5,118,611 A 6/1992 Smith et al.  
5,120,525 A 6/1992 Goldenberg et al.  
5,130,118 A 7/1992 Johnson et al.  
5,162,504 A 11/1992 Horoszewicz  
5,198,208 A 3/1993 Berg et al.  
5,208,324 A 5/1993 Klaveness et al.  
5,217,704 A 6/1993 Johnson et al.  
5,227,471 A 7/1993 Wright, Jr.  
5,229,289 A 7/1993 Kjeldsen et al.  
5,256,395 A 10/1993 Barbet et al.  
5,314,996 A 5/1994 Wright, Jr.

(Continued)

## FOREIGN PATENT DOCUMENTS

EP 0 208 531 B1 1/1987  
EP 0 232 751 B1 8/1987  
EP 0 233 619 B1 8/1987  
EP 0 279 397 B1 8/1988  
EP 0 292 689 B1 11/1988  
EP 0 299 795 A1 1/1989  
EP 0 315 188 B1 5/1989  
EP 0 382 583 B1 8/1990  
EP 0 392 423 A2 10/1990  
EP 0 466 200 AW 1/1992

(Continued)

## OTHER PUBLICATIONS

Bowie et al. (Science, 1990, 247:1306-1310).  
Skolnick et al. (TIBTECH 18:34-39, 2000).  
Ibragimova and Eade (Biophysical Journal, Oct. 1999, vol. 77, pp. 2191-2198).  
Rudikoff et al. (PNAS, USA, 1982, 79: 1979-1983).

(Continued)

Primary Examiner — Peter J Reddig

**(74) Attorney, Agent, or Firm** — Lihua Zheng; Mary Consalvi; Proskauer Rose LLP**(57) ABSTRACT**

Use of antibodies or binding portions thereof, probes, ligands, or other biological agents which either recognize an extracellular domain of prostate specific membrane antigen (PSMA) or bind to and are internalized with PSMA. These biological agents can be labeled and used for detection of cancerous tissues, particularly cancerous tissues proximate to or containing vascular endothelial cells, which express an extracellular domain of PSMA. The labeled biological agents can also be used to detect normal, benign hyperplastic, and cancerous prostate epithelial cells or portions thereof. They also can be used alone or bound to a substance effective to ablate or kill such cells as a therapy for prostate or other cancers. Also disclosed are four hybridoma cells lines, each of which produces a monoclonal antibody recognizing extracellular domains of PSMA of normal, benign hyperplastic, and cancerous prostate epithelial cells or portions thereof.

**28 Claims, 12 Drawing Sheets**

(56)

## References Cited

## U.S. PATENT DOCUMENTS

5,332,567 A	7/1994	Goldenberg	6,121,022 A	9/2000	Presta et al.
5,342,924 A	8/1994	Chang	6,136,311 A	10/2000	Bander
5,376,249 A	12/1994	Afeyan et al.	6,143,274 A	11/2000	Tweedle et al.
5,419,893 A	5/1995	Berg et al.	6,150,508 A	11/2000	Murphy et al.
5,474,756 A	12/1995	Tweedle et al.	6,193,966 B1	2/2001	Deo et al.
5,489,525 A	2/1996	Pastan	6,197,298 B1	3/2001	Chang
5,518,889 A	5/1996	Ladner et al.	6,200,765 B1	3/2001	Murphy et al.
5,523,210 A	6/1996	Paulus	6,201,167 B1	3/2001	Pothier
5,530,101 A	6/1996	Queen et al.	6,241,961 B1	6/2001	Benes et al.
5,531,978 A	7/1996	Berg et al.	6,248,516 B1	6/2001	Winter et al.
5,534,254 A	7/1996	Huston et al.	6,261,535 B1	7/2001	Thorpe et al.
5,538,866 A	7/1996	Israeli et al.	6,284,742 B1	9/2001	Curriel et al.
5,565,562 A	10/1996	Parker et al.	6,294,391 B1	9/2001	Badley et al.
5,578,484 A	11/1996	Horoszewicz	6,312,694 B1	11/2001	Thorpe et al.
5,582,996 A	12/1996	Curtis	6,329,503 B1	12/2001	Afar et al.
5,591,828 A	1/1997	Bosslet et al.	6,331,175 B1	12/2001	Goldenberg
5,599,677 A	2/1997	Dowell et al.	6,340,701 B1	1/2002	Chari et al.
5,627,078 A	5/1997	Karl et al.	6,342,219 B1	1/2002	Thorpe et al.
5,637,481 A	6/1997	Ledbetter et al.	6,342,587 B1	1/2002	Barbas, III et al.
5,639,879 A	6/1997	Mease et al.	6,361,774 B1	3/2002	Griffiths et al.
5,660,827 A	8/1997	Thorpe et al.	6,368,596 B1	4/2002	Ghetie et al.
5,674,470 A	10/1997	Tweedle et al.	6,383,759 B1	5/2002	Murphy et al.
5,688,690 A	11/1997	Valiante et al.	6,387,350 B2	5/2002	Goldenberg
5,693,477 A	12/1997	Cornell et al.	6,399,068 B1	6/2002	Godlenberg
5,697,902 A	12/1997	Goldenberg	6,458,933 B1	10/2002	Hansen
5,705,614 A	1/1998	Ring	6,492,123 B1	12/2002	Holliger et al.
5,712,136 A	1/1998	Wickham et al.	6,569,432 B1	5/2003	Israeli et al.
5,747,035 A	5/1998	Presta et al.	6,602,684 B1	8/2003	Umana et al.
5,762,930 A	6/1998	Fanger et al.	6,649,163 B1	11/2003	Bander
5,763,202 A	6/1998	Horoszewicz	6,683,162 B2	1/2004	Scheinberg et al.
5,776,427 A	7/1998	Thorpe et al.	6,709,844 B1	3/2004	Levy
5,804,602 A	9/1998	Slusher et al.	6,767,711 B2	7/2004	Bander
5,821,333 A	10/1998	Carter et al.	6,770,450 B1 *	8/2004	Bander ..... 435/7.23
5,830,473 A	11/1998	Thierfelder	6,824,780 B1	11/2004	Devaux et al.
5,830,478 A	11/1998	Raso et al.	6,833,438 B1	12/2004	Afar et al.
5,837,242 A	11/1998	Holliger et al.	6,835,866 B1	12/2004	Mangelsdorf et al.
5,837,821 A	11/1998	Wu	6,861,234 B1	3/2005	Simard et al.
5,840,854 A	11/1998	Hellstrom et al.	6,869,620 B2	3/2005	Moore
5,844,094 A	12/1998	Hudson et al.	6,870,034 B2	3/2005	Breece et al.
5,846,519 A	12/1998	Tweedle et al.	6,887,975 B2	5/2005	Afar et al.
5,851,527 A	12/1998	Hansen	6,953,668 B1	10/2005	Israeli et al.
5,852,186 A	12/1998	Sodroski et al.	6,962,981 B1	11/2005	Murphy et al.
5,855,866 A	1/1999	Thorpe et al.	6,972,324 B2	12/2005	Adolf et al.
5,861,156 A	1/1999	George et al.	6,977,074 B2	12/2005	Kundig et al.
5,863,538 A	1/1999	Thorpe et al.	6,994,851 B1	2/2006	Kundig et al.
5,863,765 A	1/1999	Berry et al.	7,037,647 B1	5/2006	Israeli et al.
5,869,049 A	2/1999	Noelle et al.	7,045,605 B2	5/2006	Bander et al.
5,869,053 A	2/1999	Stern et al.	7,053,186 B2	5/2006	Afar et al.
5,869,620 A	2/1999	Whitlow et al.	7,070,782 B1	7/2006	Israeli et al.
5,876,691 A	3/1999	Chester et al.	7,105,159 B1	9/2006	Israeli et al.
5,877,289 A	3/1999	Thorpe et al.	7,112,412 B1 *	9/2006	Bander ..... 435/7.23
5,877,291 A	3/1999	Mezes et al.	7,163,680 B2	1/2007	Bander
5,932,448 A	8/1999	Tso et al.	7,166,714 B2	1/2007	Afar et al.
5,935,818 A	8/1999	Israeli et al.	7,192,586 B2	3/2007	Bander
5,942,229 A	8/1999	Noelle et al.	7,232,682 B2	6/2007	Simard et al.
5,951,982 A	9/1999	Zöller et al.	7,235,641 B2	6/2007	Kufer et al.
5,958,474 A	9/1999	Lee et al.	7,319,006 B2	1/2008	Afar et al.
5,959,083 A	9/1999	Bosslet et al.	7,323,553 B2	1/2008	Fahrner et al.
5,965,132 A	10/1999	Thorpe et al.	7,364,729 B2	4/2008	Kundig et al.
5,980,896 A	11/1999	Hellstrom et al.	7,375,078 B2	5/2008	Feng
5,989,830 A	11/1999	Davis et al.	7,390,654 B2	6/2008	Levy
5,990,275 A	11/1999	Whitlow et al.	7,399,461 B2	7/2008	Heston et al.
6,004,554 A	12/1999	Thorpe et al.	7,435,416 B2	10/2008	Devaux et al.
6,004,555 A	12/1999	Thorpe et al.	7,452,539 B2	11/2008	Emery et al.
6,010,902 A	1/2000	Ledbetter et al.	7,455,991 B2	11/2008	Afar et al.
6,022,524 A	2/2000	Maisano et al.	7,485,299 B2	2/2009	Afar et al.
6,030,792 A	2/2000	Otterness et al.	7,485,704 B2	2/2009	Fahrner et al.
6,036,955 A	3/2000	Thorpe et al.	7,494,646 B2	2/2009	Jakobovits et al.
6,051,230 A	4/2000	Thorpe et al.	7,498,298 B2	3/2009	Doronina et al.
6,071,490 A	6/2000	Griffiths et al.	7,514,078 B2	4/2009	Bander et al.
6,083,763 A	7/2000	Balch	7,517,670 B2	4/2009	Umana et al.
6,093,399 A	7/2000	Thorpe et al.	7,521,541 B2	4/2009	Eigenbrot et al.
6,096,871 A	8/2000	Presta et al.	7,524,813 B2	4/2009	Zundel et al.
6,099,841 A	8/2000	Hillan et al.	7,541,441 B2	6/2009	Rosen et al.
6,107,090 A	8/2000	Bander	7,575,749 B2	8/2009	Afar et al.
			7,595,379 B2	9/2009	Gudas et al.
			7,611,904 B2	11/2009	Afar et al.
			7,612,181 B2	11/2009	Wu et al.
			7,622,569 B2	11/2009	Raitano et al.

(56)

## References Cited

## U.S. PATENT DOCUMENTS

7,642,054 B2 1/2010 Afar et al.  
 7,662,936 B2 2/2010 Kadkhodayan et al.  
 7,666,414 B2 2/2010 Bander  
 7,666,425 B1 2/2010 Bander  
 7,727,533 B2 6/2010 Afar et al.  
 7,745,394 B2 6/2010 Doronina et al.  
 7,754,681 B2 7/2010 Feng  
 7,807,799 B2 10/2010 Fahrner et al.  
 7,820,166 B2 10/2010 Lanzavecchia  
 7,838,637 B2 11/2010 Kontermann et al.  
 7,855,275 B2 12/2010 Eigenbrot et al.  
 7,867,483 B2 1/2011 Delcayre et al.  
 7,884,179 B2 2/2011 Faris et al.  
 7,888,035 B2 2/2011 Klass et al.  
 7,897,356 B2 3/2011 Klass et al.  
 7,906,329 B2 3/2011 Umana et al.  
 7,928,201 B2 4/2011 Afar et al.  
 7,939,503 B2 5/2011 Jakobovits et al.  
 7,947,276 B2 5/2011 Jakobovits et al.  
 7,947,459 B2 5/2011 Hubert et al.  
 7,947,839 B2 5/2011 Gazzard et al.  
 7,960,109 B2 6/2011 Hessels et al.  
 7,964,566 B2 6/2011 Doronina et al.  
 7,964,567 B2 6/2011 Doronina et al.  
 7,968,307 B2 6/2011 Afar et al.  
 7,989,434 B2 8/2011 Feng  
 7,994,135 B2 8/2011 Doronina et al.  
 7,998,701 B2 8/2011 Chua et al.  
 8,007,994 B2 8/2011 Mangelsdorf et al.  
 8,008,442 B2 8/2011 Jakobovits et al.  
 8,012,937 B2 9/2011 Raitano et al.  
 8,013,128 B2 9/2011 Gudas et al.  
 8,013,135 B2 9/2011 Jakobovits et al.  
 2002/0004215 A1 1/2002 Osbourn et al.  
 2002/0037289 A1 3/2002 Thorpe et al.  
 2002/0119096 A1 8/2002 Griffiths  
 2002/0119153 A1 8/2002 Thorpe et al.  
 2002/0132979 A1 9/2002 Chen  
 2002/0136689 A1 9/2002 Reiter et al.  
 2003/0105000 A1\* 6/2003 Pero et al. .... 514/12  
 2003/0118583 A1 6/2003 Emery et al.  
 2003/0170228 A1 9/2003 Ashkenazi et al.  
 2003/0175900 A1 9/2003 Ashkenazi et al.  
 2003/0211096 A1 11/2003 Ashkenazi et al.  
 2004/0018519 A1 1/2004 Wright  
 2004/0033511 A1 2/2004 Pfizenmaier et al.  
 2004/0038339 A1 2/2004 Kufer et al.  
 2004/0162411 A1 8/2004 Lanzavecchia  
 2004/0180002 A1\* 9/2004 Young et al. .... 424/1.49  
 2004/0241817 A1 12/2004 Umana et al.  
 2005/0026178 A1 2/2005 Nilsen-Hamilton  
 2005/0136050 A1 6/2005 Kufer et al.  
 2005/0175618 A1 8/2005 Carroll et al.  
 2005/0215769 A1 9/2005 Breece et al.  
 2005/0232929 A1 10/2005 Kadkhodayan et al.  
 2005/0272128 A1 12/2005 Umana et al.  
 2006/0062793 A1 3/2006 Webb et al.  
 2006/0159689 A1 7/2006 Chiang et al.  
 2006/0234226 A1 10/2006 Fahner et al.  
 2006/0234271 A1 10/2006 Su  
 2006/0269540 A1 11/2006 Robert et al.  
 2006/0275312 A1 12/2006 Chua et al.  
 2007/0059306 A1 3/2007 Grosmaire  
 2007/0134243 A1 6/2007 Gazzard et al.  
 2007/0212331 A1 9/2007 Baldassare et al.  
 2007/0243950 A1 10/2007 Billings  
 2007/0253950 A1 11/2007 Jacobsen  
 2007/0286858 A1 12/2007 Clancy  
 2008/0171040 A1 7/2008 Ebens et al.  
 2008/0206192 A1 8/2008 Moller et al.  
 2008/0213256 A1 9/2008 Kufer et al.  
 2008/0213921 A1 9/2008 Robertson et al.  
 2008/0227736 A1 9/2008 Chen et al.  
 2008/0267872 A1 10/2008 Raitano et al.  
 2008/0279850 A1 11/2008 Brady et al.

2008/0305105 A1 12/2008 Kufer et al.  
 2008/0305476 A1 12/2008 Robertson et al.  
 2009/0004109 A1 1/2009 Jakobovits et al.  
 2009/0022738 A1 1/2009 Hofmeister et al.  
 2009/0041758 A1 2/2009 Glaser  
 2009/0041791 A1 2/2009 Feng  
 2009/0053223 A1 2/2009 Hoffmann et al.  
 2009/0099344 A1 4/2009 Fahrner et al.  
 2009/0136475 A1 5/2009 Barth  
 2009/0155290 A1 6/2009 Carroll et al.  
 2009/0214539 A1 8/2009 Grosmaire  
 2009/0226465 A1 9/2009 Jackson  
 2009/0252729 A1 10/2009 Farrington et al.  
 2009/0272169 A1 11/2009 Pan  
 2009/0275081 A1 11/2009 Barat et al.  
 2009/0280120 A1 11/2009 Bander et al.  
 2009/0286258 A1 11/2009 Kaur et al.  
 2009/0311181 A1 12/2009 Wu et al.  
 2010/0003766 A1 1/2010 Eigenbrot et al.  
 2010/0034837 A1 2/2010 Beria et al.  
 2010/0047239 A1 2/2010 Wu et al.  
 2010/0058803 A1 3/2010 Ransbarger  
 2010/0069616 A1 3/2010 Wu et al.  
 2010/0111856 A1 5/2010 Gill et al.  
 2010/0135900 A1 6/2010 Cerveny  
 2010/0184046 A1 7/2010 Klass et al.  
 2010/0189651 A1 7/2010 Stagliano et al.  
 2010/0215581 A1 8/2010 Hoffmann  
 2010/0255479 A1 10/2010 Mikolajczyk et al.  
 2010/0266491 A1 10/2010 Farokhzad et al.  
 2010/0267933 A1 10/2010 Wilson  
 2010/0278919 A1 11/2010 Denes et al.  
 2010/0297004 A1 11/2010 Wu et al.  
 2010/0303715 A1 12/2010 Israeli  
 2010/0303814 A1 12/2010 Cizeau et al.  
 2010/0303821 A1 12/2010 Ashman  
 2010/0310452 A1 12/2010 Israeli  
 2010/0310584 A1 12/2010 Carroll et al.  
 2011/0006466 A1 1/2011 Ichikawa  
 2011/0009001 A1 1/2011 Chen  
 2011/0020327 A1 1/2011 Moya et al.  
 2011/0069019 A1 3/2011 Carpendale et al.  
 2011/0076287 A1 3/2011 Cohen et al.  
 2011/0081345 A1 4/2011 Moore  
 2011/0086050 A1 4/2011 Presta  
 2011/0104059 A1 5/2011 St. Croix et al.  
 2011/0110852 A1 5/2011 Miller et al.  
 2011/0117023 A1 5/2011 Yamauchi  
 2011/0123532 A1 5/2011 Gurney et al.  
 2011/0137017 A1 6/2011 Eigenbrot et al.  
 2011/0207155 A1 8/2011 Pengo et al.  
 2011/0227023 A1 9/2011 Bethune et al.

## FOREIGN PATENT DOCUMENTS

EP 0 495 878 B1 7/1992  
 EP 0 594 739 B1 5/1994  
 EP 0 125 023 11/1994  
 EP 0668777 8/1995  
 EP 0 956 506 7/1996  
 EP 1 005 494 3/1997  
 EP 0 882 454 AZ 12/1998  
 EP 1 550 729 7/2005  
 EP 1629011 3/2006  
 EP 1 997 514 12/2008  
 EP 2226394 9/2010  
 EP 2260858 12/2010  
 JP 2003-504414 2/2003  
 WO WO 86/06384 11/1986  
 WO WO 88/02635 4/1988  
 WO WO 89/00557 1/1989  
 WO WO 89/06979 8/1989  
 WO 91/07493 5/1991  
 WO WO 91/09967 7/1991  
 WO WO 91/15466 10/1991  
 WO WO 93/15199 8/1993  
 WO WO 93/17715 9/1993  
 WO WO 93/19668 10/1993  
 WO WO 94/04702 3/1994

(56)

## References Cited

## FOREIGN PATENT DOCUMENTS

WO	WO 94/09820	5/1994
WO	WO 94/26297	11/1994
WO	WO 95/26206	10/1995
WO	WO 95/31444	11/1995
WO	96/08570	3/1996
WO	WO 96/26272	8/1996
WO	WO 96/39185	12/1996
WO	WO 96/40245	12/1996
WO	WO 97/32862	9/1997
WO	WO 97/35616	10/1997
WO	WO 99/43710	9/1999
WO	WO 99/56779 A1	11/1999
WO	WO 00/14234 A1	3/2000
WO	WO 00/50457	8/2000
WO	WO 00/52473	9/2000
WO	WO 00/74729	12/2000
WO	WO 01/05427 A1	1/2001
WO	WO 01/09303 A2	2/2001
WO	WO 01/82963 A2	11/2001
WO	WO 02/22680	3/2002
WO	WO 03/038098	5/2003
WO	WO 2005/026334 A2	3/2005
WO	WO 2005/043165 A2	5/2005
WO	WO 2005/061547 A2	7/2005
WO	WO 2005/068616	7/2005
WO	WO 2007/064345 A2	6/2007
WO	WO 2007/109321	9/2007
WO	WO 2007/137117 A2	11/2007
WO	WO 2009/017823	2/2009
WO	WO 2009/032949	3/2009
WO	WO 2009/039854 A2	4/2009
WO	WO 2009/076099 A1	6/2009
WO	WO 2009/082443 A2	7/2009
WO	WO 2009/097128	8/2009
WO	WO 2010/037395 A2	4/2010
WO	WO 2010/037397 A1	4/2010
WO	WO 2010/102195 A2	9/2010
WO	WO 2011/000054	1/2011
WO	WO 2011/056983 A1	5/2011
WO	WO 2011/069019	6/2011
WO	WO 2011/075786	6/2011
WO	WO 2011/090762 A1	7/2011
WO	WO 2011/109440 A1	9/2011

## OTHER PUBLICATIONS

Coleman et al. (Research in Immunology, 1994; 145(1): 33-36).\*

Abaza et al. (Journal of Protein Chemistry, vol. 11, No. 5, 1992, pp. 433-444).\*

Burgess et al. (J of Cell Bio. 111:2129-2138, 1990).\*

Gussow et al. (1991, Methods in Enzymology 203:99-121).\*

Kaiser (Science, 2006, 313: 1370).\*

Gura (Science, 1997, 278:1041-1042).\*

Morris et al. (Clin. Cancer Res. May 1, 2007 13(9): 2707-2712).\*

Dillman (Annals of Internal Medicine, 1989 111:592-603).\*

Baselga, J., et al., "Phase II Study of Weekly Intravenous Recombinant Humanized Anti-p185<sup>HER2</sup> Monoclonal Antibody in Patients with HER2/*neu*-Overexpressing Metastatic Breast Cancer," Journal of Clinical Oncology, vol. 14, No. 3, pp. 737-744, 1996.

Clamp, A.R., et al., "The clinical potential of antiangiogenic fragments of extracellular matrix proteins," British Journal of Cancer, vol. 93, pp. 967-972, 2005.

Curti, B.D., "Physical barriers to drug delivery in tumors," Critical Reviews in Oncology/Hematology, vol. 14, pp. 29-39, 1993.

Dillman, R.O., "Monoclonal Antibodies for Treating Cancer," Annals of Internal Medicine, vol. 111, pp. 592-603, 1989.

Gura, T., "Systems for Identifying New Drugs Are Often Faulty," Science, vol. 278, pp. 1041-1042, 1997.

Kaiser, J., "First Pass at Cancer Genome Reveals Complex Landscape," Science, vol. 313, p. 1370, 2006.

McDevitt, M.R., et al., "An  $\alpha$ -Particle Emitting Antibody ([<sup>213</sup>Bi]J591) for Radioimmunotherapy of Prostate Cancer," Cancer Research, vol. 60, pp. 6095-6100, 2000.

Winter, G., et al., "Humanized antibodies," TIPS, vol. 14, pp. 139-143, 1993.

Barren et al. (1997), "Monoclonal Antibody 7E11.C5 Staining of Viable LNCaP Cells", Prostate 30(1):65-8.

Carter et al. (1996), "Prostate-specific Membrane Antigen is a Hydrolase with Substrate and Pharmacologic Characteristics of a Neuropeptidase", Proc. Natl. Acad. Sci. U.S.A. 93:749-751.

Diamond et al. (1997), "Monoclonal Antibody 225 Blockade of Prostate Specific Membrane Antigen (PSM) Expression: Potential Novel Therapy for Prostate Cancer", Journal of Urology 157(4 suppl):226 (Abstract 884).

Fair et al. (1997), "Prostate Specific Membrane Antigen", Prostate 32(2):140-8.

Israeli et al. (1997), "Prostate Specific Membrane Antigen and Other Prostatic Tumor Markers on the Horizon", Urological Clinics of North America 24(2):439-50.

Leek et al. (1995), "Prostate-Specific Membrane Antigen: Evidence for the Existence of a Second Related Human Gene", British Journal of Cancer 72:583-588.

Murphy et al. (1995), "Comparison of Prostate Specific Antigen, Prostate Specific Membrane Antigen, and LNCaP-Based Enzyme-Linked Immunosorbent Assays in Prostatic Cancer Patients and Patients With Benign Prostatic Enlargement", The Prostate 26:164-168.

Murphy et al. (1995), "Comparison of Prostate Specific Membrane Antigen, and Prostate Specific Antigen Levels in Prostatic Cancer Patients", Anticancer Res. 15:1473-1480.

Pinto et al. (1996), "Prostate-Specific Membrane Antigen: A Novel Folate Hydrolase in Human Prostatic Carcinoma Cells", Clinical Cancer Research 2(9):1445-51.

Su et al. (1995), "Alternatively Spliced Variants of Prostate-specific Membrane Antigen RNA: Ratio of Expression as a Potential Measurement of Progression", Cancer Research 55:1441-1443.

Troyer et al. (1994), "Subcellular Localization of the 7E11-C5 Prostate Specific Antigen", Proc. Am. Assoc. Cancer Research 35:283 (Abstract 1688).

Uria et al. (1997), "Prostate Specific Membrane Antigen in Breast Carcinoma", The Lancet 349(9065):1601.

Wright (1990), "Characterization of a New Prostate Carcinoma-Associated Marker: 7E11-C5", Antibody Immunoconjugates and RadioPharmaceuticals 3:Abstract 193.

Chang et al., "Prostate-Specific Membrane Antigen: Much More Than a Prostate Cancer Marker", *Molecular Urology* 3(3):313-321 (1999).

Chang et al., "The clinical role of prostate-specific membrane antigen (PSMA)", *Urologic Oncology* 7:7-12 (2002).

Chang et al., "Prostate-specific Membrane Antigen Is Produced in Tumor-associated Neovasculature", *Clinical Cancer Research* 674(5):2674-2681 (1999).

Chang et al., "Five Different Anti-Prostate-specific Membrane Antigen (PSMA) Antibodies Confirm PSMA Expression in Tumor-associated Neovasculature", *Cancer Research* 59:3192-3198 (1999).

Chang et al., "Comparison of anti-prostate-specific membrane antigen antibodies and other immunomarkers in metastatic prostate carcinoma", *Urology* 57(6):1179-1183 (2001).

Fracasso et al., "Anti-tumor Effects of Toxins Targeted to the Prostate Specific Membrane Antigen", *The Prostate* 53:9-23 (2002).

Gong et al., "Prostate-specific membrane antigen (PSMA)-specific monoclonal antibodies in the treatment of prostate and other cancers", *Cancer and Metastasis Reviews* 18:483-490 (1999).

Gong et al., "Overview of Evolving Strategies Incorporating Prostate-Specific Membrane Antigen as Target for Therapy", *Molecular Urology* 4(3):217-223 (2000).

Grauer et al., "Identification, Purification, and Subcellular Localization of Prostate-specific Membrane Antigen PSM Protein in the LNCaP Prostatic Carcinoma Cell Line", *Cancer Research* 58:4787-4789 (1998).

Liu et al., "Monoclonal Antibodies to the Extracellular Domain of Prostate-specific Membrane Antigen Also React with Tumor Vascular Endothelium", *Cancer Research* 57:3629-3634 (1997).

(56)

## References Cited

## OTHER PUBLICATIONS

- Smith-Jones et al., "In Vitro Characterization of Radiolabeled Monoclonal Antibodies Specific for the Extracellular Domain of Prostate-specific Membrane Antigen", *Cancer Research* 60:5237-5243 (2000).
- Sokoloff et al., "A Dual-Monoclonal Sandwich Assay for Prostate-specific Membrane Antigen: Levels in Tissues, Seminal Fluid and Urine", *The Prostate* 43:150-157 (2000).
- Wang et al., "Identification of Prostate Specific Membrane Antigen (PSMA) as the Target of Monoclonal Antibody 107-1A4 by Proteinchip®; Array, Surface-enhanced Laser Desorption/ionization (SELDI) Technology", *Int. J. Cancer* 92:871-876 (2001).
- Jain, "Barriers to Drug Delivery in Solid Tumors", *Scientific American* Jul. 1994:58-65.
- Weiner, "An Overview of Monoclonal Antibody Therapy of Cancer", *Seminars Oncology* 26:41-50 (1999).
- Dillman et al. (1988), "Toxicities Associated with Monoclonal Antibody Infusions in Cancer Patients", *Mol. Biother.* 1(2):81-85.
- Dillman et al. (1994), "Human Anti-Mouse Antibody Response in Cancer Patients Following Single Low-Dose Injections of Radiolabeled Murine Monoclonal Antibodies", *Cancer Biotherapy* 9(1):17-28.
- Harlow and Lane (1988), "Antibodies: A laboratory manual", Cold Spring Harbor Laboratory, p. 139-243.
- Heston (1997), "Characterization and Glutamyl Preferring Carboxypeptidase Function of Prostate Specific Membrane Antigen: A Novel Folate Hydrolase", *Urology* 49(3A):104-112.
- Horoszewicz et al. (1987), "Monoclonal Antibodies to a New Antigenic Marker in Epithelial Prostatic Cells and Serum of Prostatic Cancer Patients", *Anticancer Research* 7(5B):927-936.
- Israeli et al. (1993), "Molecular Cloning of a Complementary DNA Encoding a Prostate-Specific Membrane Antigen", *Cancer Research* 53(2):227-230.
- Israeli et al. (1994), "Expression of the Prostate-Specific Membrane Antigen", *Cancer Research* 54(7):1807-1811.
- Jain, R.K. (1990), "Vascular and interstitial barriers to delivery of therapeutic agents in tumors", *Cancer and Metastasis Reviews* 9(3):253-266.
- Leung et al. (1986), "Selection of a Monoclonal Antibody to a New Prostate Cancer Marker for in Vivo Clinical Trials", 6th International Congress of Immunology, p. 516 (Abstract 4.15.19).
- Liu et al. (1997), "Monoclonal Antibodies to the Extracellular Domain of Prostate-specific Membrane Antigen also React with Tumor Vascular Endothelium", *Cancer Research* 57(18):3629-3634.
- Liu, et al. (1998), "Constitutive and Antibody-Induced Internalization of Prostate-Specific Membrane Antigen", *Cancer Research* 58(18):4055-4060.
- Murphy et al. (1996), "Measurement of Prostate-Specific Membrane Antigen in the Serum With a New Antibody", *The Prostate* 28(4):266-271.
- Rochon et al. (1994), "Western Blot Assay for Prostate-Specific Membrane Antigen in Serum of Prostate Cancer Patients", *The Prostate* 25(4):219-223.
- Schlom (1991), "Monoclonal antibodies: They're more and less than you think", *Molecular Foundations of Oncology*, ed. Broder, Williams & Wilkins, p. 95-134.
- Silver et al. (1997), "Prostate-specific Membrane Antigen Expression in Normal and Malignant Human Tissues", *Clinical Cancer Research* 3:81-85.
- Troyer et al. (1995), "Biochemical Characterization and Mapping of the 7E11-C5.3 Epitope of the Prostate-Specific Membrane Antigen", *Urol Oncol* 1:29-37.
- Troyer et al. (1995), "Detection and Characterization of the Prostate-Specific Membrane Antigen (PSMA) in Tissue Extracts and Body Fluids", *International Journal of Cancer* 62(5):552-558.
- Troyer et al. (1997), "Location of prostate-specific membrane antigen in the LNCaP prostate carcinoma cell line", *Prostate* 30(4):232-242.
- Wang et al. (1988), "Monoclonal Antibody Assays for Prostatic Tumor", *Immunol Ser* 39:195-219.
- Wright et al. (1995), "Expression of Prostate-Specific Membrane Antigen in Normal, Benign, and Malignant Prostate Tissues", *Urol Oncol*, 1:18-28.
- Yang et al. (1998), "Alpha particle emitter therapy of micrometastases: 213Bi-J5 (anti-PSMA) treatment of LNCaP spheroids", *Proceedings of the American Association for Cancer Research* 39:440 (Abstract #2996).
- Coleman et al., "Fundamental Immunology", Wm. C. Brown Publishers, p. 76.
- ATCC Deposit #HB9131, dated Jun. 24, 1986.
- Thomas et al., "Antibodies for tumour immunodetection and methods for antibody radiolabelling", in *Antibodies vol. II A practical approach*, Oxford University Press, 1988.
- Panka et al., *Proc. Natl. Acad. Sci. USA* 85:3080-3084, 1998.
- Rudikoff et al., *Proc. Natl. Acad. Sci. USA* 79:1979, 1982.
- Bernard et al., "A Unique Epitope on the CD2 Molecule Defined by the Monoclonal Antibody 9-1: Epitope-Specific Modulation of the E-Rosette Receptor and Effects on T-Cell Functions", *Human Immunol.* 1986; 17: 388-405.
- Boyer et al., "Relative cytotoxic activity of immunotoxins reactive with different epitopes on the extracellular domain of the c-erbB-1 (HER-2/neu) gene product p185", *Int. J. Cancer* 1999; 82: 525-531.
- Campbell et al., "Monoclonal Antibody Therapy for Lymphoma", *Blood Reviews* 17:143-152, 2003.
- Dennis, "Off by a Wisker", *Nature* 442:739-741, 2006.
- De Santes et al., "Radiolabeled antibody targeting of the HER-2/neu Oncoprotein", *Cancer Res. Apr. 1, 1992; 52: 1916-1923.*
- Evans et al., "Vaccine therapy for cancer—fact or fiction?" *QJM*, Jun. 1999, vol. 92, No. 6, pp. 299-307.
- George et al., "Differential effects of anti-β2-glycoprotein I antibodies on endothelial cells and on the manifestations of experimental antiphospholipid syndrome", *Circulation* 1998; 97 900-906.
- Greenspan et al., "Defining epitopes: It's not as easy as it seems", *Nature Biotechnology*. 1999; 7: 936-937.
- Henry et al., "A prostate-specific membrane antigen-targeted monoclonal antibody-chemotherapeutic conjugate designed for the treatment of prostate cancer", *Cancer Res. Nov. 1, 2004; 64: 7995-8001.*
- Hopp et al., "A Computer Program for Predicting Protein Antigenic Determinants", *Mol. Immunol.* 20:4 pp. 483-489, 1983.
- Jain, "Barriers to Drug Delivery in Solid Tumors", *Scientific American* 271:58-65, 1994.
- Janeway and Travers, *Immuno Biology 3<sup>rd</sup>*. Ed. (1997), extracts from chapter 3 pp. 3:23-24, Chapter 8, pp. 8:18-19, and Chapter 13, pp. 13:17-19.
- Jiang et al., "A novel peptide isolated from a phage display peptide library with trastuzumab can mimic antigen epitope of HER-2", *J. Biol. Chem.* Feb. 11, 2005; 280(6): 4656-4662.
- Kim et al., "Both the epitope specificity and isotype are important in the antitumor effect of monoclonal antibodies against HER-2/neu antigen", *Int. J. Cancer* 2002; 102: 428-434.
- Kinoshita et al., "Targeting epitopes in prostate-specific membrane antigen for antibody therapy of prostate cancer", *Prost. Cancer Prost. Dis.* 2005; 8: 359-363.
- Kipps et al., "Importance of Immunoglobulin Isotype in Human Antibody-Dependent, Cell-Mediated Cytotoxicity Directed by Murine Monoclonal Antibodies", *J. Exp. Med.* 161(1):1-17, 1985.
- Lewis et al., "Differential responses of human tumor cell lines to anti-p185<sup>HER2</sup> monoclonal antibodies", *Cancer Immunol. Immunother.* 1993; 37:255-263.
- Li et al., "In vitro and preclinical targeted alpha therapy of human prostate cancer with Bi-213 labeled J591 antibody against the prostate specific membrane antigen", *Prostatic Dis.* 2002; 5 (1): 36-46.
- Masui et al., "Mechanism of Antitumor Activity in Mice for Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies with Different Isotypes", *Cancer Res.* 46 (11):5592-5598, 1986.
- Morris et al., "Pilot trial of unlabeled and indium-111-labeled anti-prostate-specific membrane antigen antibody J591 for castrate metastatic prostate cancer", *Clin. Cancer Res.* Oct. 15, 2005; 11(2): 7454-7461.

(56)

## References Cited

## OTHER PUBLICATIONS

- Mwawech-Fauceglia et al., "Prostate-specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using multiple tumor tissue microarray technique" *Histopathology*, 50(4):472-483, 2007.
- Persiani et al., "In vivo antitumor effect of methotrexate conjugated to a monoclonal IgM antibody specific for state-specific embryonic antigen-1, on MH-15 mouse teratocarcinoma", *Cancer Immunol Immunother*, 29:167-170, 1989.
- Pettersen et al., "CD47 signals T cell death", *J. Immunol.* Jun. 15, 1999; 162 (12): 7031-7040.
- Press et al., "Ricin A-chain containing immunotoxins directed against different epitopes on the CD2 molecule differ in their ability to kill normal and malignant T cells", *J. Immunol.* Dec. 15, 1988; 141 (12): 4410-4417.
- Rajasekaran et al., "A Novel Cytoplasmic Tail MXXXL Motif Mediates the Internalization of Prostate-specific Membrane Antigen", *Molecular Biology of the Cell*, 14:4835-4845, 2003.
- Riemer et al., "Matching of trastuzumab (Herceptin®) epitope mimics onto the surface of her-2/neu—a new method of epitope definition", *Mol. Immunol.* 2005; 42: 1121-1124.
- Russell et al., "Cytotoxic properties of immunoconjugates containing melittin-like peptide 101 against prostate cancer: in vitro and in vivo studies", *Cancer Immunol. Immunother*, May 2004; 53(5): 411-421.
- Shinnick et al., "Peptide-elicited protein-reactive antibodies in molecular biology and medicine", *J. Invest. Dermatol.* Jul. 1984; 83 (1 Suppl): 112s-115s.
- Stancoviski et al., "Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth", *Proceedings of the National Academy of Science USA*. 1991; 88: 8691-8695.
- Tazzari et al., "An immunotoxin containing a rat IgM monoclonal antibody (Campath 1) and a saporin 6: effect on T lymphocytes and hemopoietic cells", *Cancer Immunol Immunother*, 26:231-236, 1988.
- Usui et al., "Evaluation of Ricin A Chain-Containing Immunotoxins Directed Against Glycolipid and Glycoprotein on Mouse Lymphoma Cells", *Acta Med Okayama*, 48(6):305-309, 1994.
- Vuist et al., "Two Distinct Mechanisms of Antitumor Activity Mediated by the Combination of Interleukin 2 and Monoclonal Antibodies" *Cancer Res.*, 50(18):5767-5772, 1990.
- Wiedlocha et al., "Specific Killing of Mouse Leukemic Cells with Ricin A-Chain Immunotoxin", *Archivum Immunologiae et Therapiac Experimentalis*, 37:101-113, 1989.
- Wiels et al., "Properties of Immunotoxins Against a Glycolipid Antigen Associated with Burkitt's Lymphoma", *Cancer Research*, 44:129-133, 1984.
- Xu et al., "Antibody-induced growth inhibition is mediated through immunochemically and functionally distinct epitopes on the extracellular domain of the c-erbB-2 (HER-2/neu) gene product p185", *Int. J. Cancer* 1993; 53: 401-408.
- Elsasser-Beile et al., *The Prostate* 66:1359-1370 (2006).
- Gregor et al., *Int. J. Cancer*. 116:415-421 (2005).
- Schulke et al., *PNAS* 100:12590-12595 (2003).
- Holmes et al., *Exp. Opin. Invest. Drugs* 10:511-519 (2001).
- Barinka et al., *Protein Sci.* 13:1627-1635 (2004).
- Rovenska et al., *The Prostate* 68:171-182 (2008).
- Barinka et al., *J. Neurochem.* 80:477-487 (2002).
- Sacha et al., *Neurosci.* 144:1361-1372 (2007).
- Moffett et al., *Hybridoma*, 26:363-372 (2007).
- Hopp et al., *PNAS* 78:3824-3828 (1981).
- Lopes et al., *Cancer Res.* 50:6423-6429 (1990).
- U.S. Appl. No. 11/939,422, filed Sep. 24, 2009, Bander.
- U.S. Appl. No. 12/959,340, filed Nov. 3, 2011, Ho.
- U.S. Appl. No. 12/959,230, filed Dec. 2, 2010, Smith.
- U.S. Appl. No. 08/621,399, filed Mar. 25, 1996, Murphy et al.
- U.S. Appl. No. 12/788,477, filed May 27, 2010, Wu et al.
- U.S. Appl. No. 11/692,643, filed Mar. 28, 2007, Hudson et al.
- U.S. Appl. No. 12/676,348, filed Nov. 25, 2010, Wu.
- U.S. Appl. No. 12/537,145, filed Aug. 6, 2009, Wu et al.
- U.S. Appl. No. 13/554,306, filed Jul. 20, 2012, Wu et al.
- U.S. Appl. No. 09/357,707, filed Jul. 20, 1999, Bander.
- U.S. Appl. No. 10/367,956, filed Feb. 19, 2003, Hudson et al.
- U.S. Appl. No. 12/413,435, filed Mar. 27, 2009, Gudas.
- U.S. Appl. No. 12/363,678, filed Jan. 30, 2009, Barat et al.
- U.S. Appl. No. 12/293,860, filed Dec. 17, 2009, Wu.
- U.S. Appl. No. 11/219,563, filed Feb. 3, 2010, Blanchard.
- U.S. Appl. No. 09/147,142, filed Mar. 5, 1999, Hudson et al.
- U.S. Appl. No. 13/094,730, filed Apr. 26, 2011, Gudas.
- Adams et al., "Highly specific in vivo tumor targeting by monovalent and divalent forms of 741F8 anti-c-erbB-2 single-chain Fv," *Cancer Res.*, Sep. 1, 1993, pp. 4026-4034, vol. 53, No. 17.
- Additional Consent Form for Cornell Clinical Investigation by the New York Hospital-Cornell Medical Center, Mar. 9, 2000.
- Albrecht et al., "Development of anti-MUC1 di-scFvs for molecular targeting of epithelial cancers, such as breast and prostate cancers," *Dec. 2007*, pp. 304-313, vol. 51, No. 4.
- Alvarez et al., "Intraperitoneal Radioimmunotherapy of Ovarian Cancer with Lu-CC49: A Phase I/II Study," *Gynecologic Oncology*, 65(1):94-101 Apr. 1997.
- Atwell et al., "scFv multimers of the anti-neuraminidase antibody NC10: length of the linker between V<sub>H</sub> and V<sub>L</sub> domains dictates precisely the transition between diabodies and triabodies," *Protein Engineering*, Jul. 1999, vol. 12, No. 7, pp. 597-604.
- Bander et al., "Phase I trial of 177 Lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer," *Journal of Clinical Oncology*, Jul. 20, 2005, pp. 4591-4601, vol. 23, No. 21.
- Bander et al., "Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen", *The Journal of Urology*, vol. 170, pp. 1717-1721 (Nov. 2003).
- Bander, Neil, H., "Antibody Treatment of Prostate Cancer," CapCure Board Presentation, 18 pages, Nov. 11, 1999.
- Barat et al., "Cys-diabody quantum dot conjugates (immunoQdots) for cancer marker detection," *Bioconjug. Chem.*, Aug. 19, 2009, pp. 1474-1781, vol. 20, No. 8.
- Bendig, M.M., "Humanization of Rodent Monoclonal Antibodies by CDR Grafting," *Methods: A Companion to Methods in Enzymology*, 8:83-93, 1995.
- Carmichael et al., "The crystal structure of an anti-CEA scFv diabody assembled from T84.66 scFvs in V(L)-to-V(H) orientation: Implications for diabody flexibility," *J. Mol. Biol.*, Feb. 14, 2003, pp. 341-351, vol. 326, No. 2.
- Casset, F., et al., "A peptide mimetic of an anti-CD4 monoclonal antibody by rational design," *Biochemical and Biophysical Research Communications* 307, 2003, pp. 198-205.
- City of Hope National Medical Center, "Anti-CEA antibody T84.66 humanized," *Medical Imaging Law Weekly*, copyright 2004, <http://www.newsrx.com/newsletters/Medical-Imaging-Law-Weekly> ; dated for online publication Nov. 27, 2004.
- Colman, P.M., "Effects on amino acid sequence changes on antibody-antigen interactions," *Research in Immunology*, 145:33-36, 1994.
- Common Toxicity Criteria, Version 2.0, National Cancer Institute, Cancer Therapy Evaluation Program, Jun. 1, 1999.
- Communication pursuant to Rules 70(2) and 70a(2) EPC dated Dec. 28, 2010, received in EP Appl. No. 08799192.3, 11 pages.
- De Pascalis et al., "Grafting of "Abbreviated" Complementarity-Determining Regions Containing Specificity-Determining Residues Essential for Ligand Contact to Engineer a Less Immunogenic Humanized Monoclonal Antibody," *J. Immunol.* 169(6): 3076-3084, 2002.
- Desantes et al., "Radiolabeled Antibody Targeting of the HER-2/neu Oncoprotein," *Cancer Research* 52:1916-1923, Apr. 1, 1992.
- Desplanco et al., "Multimerization behaviour of single chain Fv variants for the tumour-binding antibody B72.3," *Protein Engineering*, Aug. 1994, vol. 7, No. 8, pp. 1027-1033.
- Extracts from Janeway and Travers, *Immunology*, 3rd Ed. 1997.
- File History, U.S. Appl. No. 08/256,156, filed Jun. 24, 1994.
- File History, U.S. Appl. No. 08/838,682, filed Apr. 9, 1997.
- File History, U.S. Appl. No. 08/895,914, filed Jul. 17, 1997.
- File History, U.S. Appl. No. 09/357,704, filed Jul. 20, 1999.

(56)

## References Cited

## OTHER PUBLICATIONS

- File History, U.S. Appl. No. 09/357,707, filed Jul. 20, 1999.
- File History, U.S. Appl. No. 09/357,708, filed Jul. 20, 1999.
- File History, U.S. Appl. No. 09/357,709, filed Jul. 20, 1999.
- File History, U.S. Appl. No. 09/929,546, filed Aug. 13, 2001.
- File History, U.S. Appl. No. 10/160,505, filed May 30, 2002.
- File History, U.S. Appl. No. 10/449,379, filed May 30, 2003.
- File History, U.S. Appl. No. 11/218,813, filed Sep. 2, 2005.
- File History, U.S. Appl. No. 11/219,563, filed Sep. 2, 2005.
- File History, U.S. Appl. No. 12/371,399, filed Feb. 13, 2009.
- File History, U.S. Appl. No. 10/690,990, filed Oct. 23, 2003.
- File History, U.S. Appl. No. 12/293,860, filed Sep. 22, 2008.
- File History, U.S. Appl. No. 12/363,678, filed Jan. 30, 2009.
- File History, U.S. Appl. No. 12/537,145, filed Aug. 6, 2009.
- File History, U.S. Appl. No. 12/676,348, filed Aug. 5, 2010.
- File History, U.S. Appl. No. 12/788,477, filed May 27, 2010.
- File History, U.S. Appl. No. 12/959,340, filed Dec. 2, 2010.
- File History, U.S. Appl. No. 13/554,306, filed Jul. 20, 2012.
- Fitzgerald et al., "Improved Tumor Targeting by Disulphide Stabilized Diabodies Expressed in *Pichia Pastoris*." *Protein Engineering* 10.10 (1997): 1221-1225.
- Forni et al., "Immunoprevention of Cancer: Is the Time Ripe?" *Cancer Research*, 60; 2571-2575, 2000.
- George et al., "Radiometal labeling of recombinant proteins by a genetically engineered minimal chelation site: technetium-99m coordination by single-chain Fv antibody fusion proteins through a C-terminal cysteinyl peptide," *Proc. Natl. Acad. Sci. USA*, Aug. 1995, vol. 92, No. 18, pp. 8358-8362.
- Glockshuber et al., "A comparison of strategies to stabilize immunoglobulin Fv-fragments," *Biochemistry*, 1990, pp. 1362-1367, vol. 29, No. 6.
- Gu et al., "Biological activity and microPET imaging properties of chimeric and humanized anti-prostate stem cell antigen (PSCA) antibodies," *Proc Amer Assoc Cancer Res.*, 2005, vol. 46, Abstract #696 [Retrieved on May 14, 2012], URL: <http://aacrmeetingabstracts.org/cgi/content/abstract/2005/1/164-b>.
- Hinman et al., "Preparation and Characterization of Monoclonal Antibody Conjugates of the Calicheamicins: A Novel and Potent Family of Antitumor Antibiotics," *Cancer Research*, 53: 3336-3342, 1993.
- Hollinger et al., "Diabodies": Small bivalent and bispecific antibody fragments," *Proc. Natl. Acad. Sci. USA*, Jul. 1993, pp. 6444-6448, vol. 90.
- Holm et al., "Functional mapping and single chain construction of the anti-Cytokeratin 8 monoclonal antibody TS1," *Molecular Immunology*, 44 (6): 1075-1084, 2007.
- Holmes et al., "PSMA Specific Antibodies and Their Diagnostic and Therapeutic Use," *Expert Opinion on Investigational Drugs*, 10 (3): 544-519 (2001).
- Hu et al., "Minibody: A Novel Engineered Anti-carcinoembryonic Antigen Antibody Fragment (Single-Chain Fv-C<sub>h</sub><sup>3</sup>) Which Exhibits Rapid, High-Level Targeting of Xenografts," *Cancer Research* 56 (Jul. 1, 1996): 3055-3061.
- International Search Report & Written Opinion dated Mar. 21, 2012 for International Application No. PCT/US2010/058803, filed Dec. 2, 2010.
- International Search Report and Written Opinion dated Apr. 22, 2009, from Int'l Appl. No. PCT/US2008/075291 (WO 2009/032949).
- International Search Report and Written Opinion dated Apr. 23, 2008, from Int'l Appl. No. PCT/US2007/007020 (WO 2007/109321).
- Israeli, Ron S. et al., "Molecular Cloning of a Complementary DNA Encoding a Prostate-Specific Membrane Antigen," *Cancer Research* 53, 227-230, Jan. 15, 1993.
- Johnson et al., "Effector cell recruitment with novel Fv-based dual-affinity re-targeting protein leads to potent tumor cytotoxicity and in vivo B-cell depletion," *J. Mol. Biol.*, Jun. 11, 2010, pp. 436-449, vol. 399, No. 3.
- Kim et al., "Anti-CD30 diabody-drug conjugates with potent antitumor activity," *Mol. Cancer Ther.*, Aug. 2008, pp. 2486-2497, vol. 7, No. 8.
- Kukis et al., "Effect of the extent of chelate substitution on the immunoreactivity and biodistribution of 2IT-BAT-Lym-1 immunoconjugates," *Cancer Research*, vol. 55, pp. 878-884 (Feb. 1, 1995).
- Leung et al., "Engineering a Unique Glycosylation Site for Site-Specific Conjugation of Haptens to Antibody Fragments," *The Journal of Immunology* 154 (1995): 5919-5926.
- Lewis et al., "An improved method for conjugating monoclonal antibodies with N-Hydroxysulfosuccinimidyl DOTA," *Bioconjugate Chem.*, vol. 12, pp. 320-324 (2001).
- Leyton et al., "Humanized radioiodinated minibody for imaging of prostate stem cell antigen-expressing tumors," *Clinical Cancer Research*, vol. 14 No. 22, pp. 7488-7496 (Nov. 15, 2008).
- Li et al., "Improved biodistribution and radioimmunoinaging with poly(ethylene glycol)-DOTA-conjugated anti-CEA diabody," *Bioconjug. Chem.*, Jan.-Feb. 2006, pp. 68-76, vol. 17, No. 1.
- Li et al., "Labeling Monoclonal Antibodies with Yttrium and Indium-DOTA Chelates: A Simple and Efficient Method," *Bioconjugate Chemistry*, 5(2): 101-104, 1994.
- Li et al., "Reduction of kidney uptake in radiometal labeled peptide linkers conjugated to recombinant antibody fragments, site-specific conjugation of DOTA-peptides to a Cys-diabody," *Bioconjugate Chem.*, 2002, pp. 985-995, vol. 13, No. 5.
- Liu et al., "Constitutive and antibody-induced internalization of prostate-specific membrane antigen," *Cancer Research*, vol. 58, pp. 4055-4060 (Sep. 1, 1998).
- Liu et al., "Eradication of large colon tumor xenografts by targeted delivery of maytansinoids," *Proc. Natl. Acad. Sci. USA*, 93:8618-8623, 1996.
- MacCallum et al., "Antibody-antigen Interactions: Contact Analysis and Binding Site Topograph," *J. Mol. Biol.* 262, 732-745, 1996.
- Marty et al., "Production of functionalized single-chain Fv antibody fragments binding to the ED-B domain of the B-isoform of fibronectin in *Pichia pastoris*," *Protein Expression and Purification*, Feb. 2001, vol. 21, Issue 1, pp. 156-164.
- McCartney et al., "Engineering disulfide-linked single-chain Fv dimers [(sFv)<sub>2</sub>] with improved solution and targeting properties: anti-digoxin 26-10 (sFv)<sub>2</sub> and anti-c-erbB-2 741F8 (sFv)<sub>2</sub> made by protein folding and bonded through C-terminal cysteinyl peptides," *Protein Eng.* 8.3 (Mar. 1995):301-14.
- McCartney et al., Refolding of single-chain Fv with C-terminal cysteine (sFv); formation of disulfide-bonded homodimers of anti-AE'r/7B-2 and anti-digoxin sFv', *Miami Short Rep.*, 1993, vol. 3, p. 91.
- Milowsky et al., "Phase I Trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer," *Journal of Clinical Oncology*, vol. 22 No. 13, pp. 2522-2531 (Jul. 1, 2004).
- Milowsky et al., "Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors," *Journal of Clinical Oncology*, vol. 25 No. 5, pp. 540-547 (Feb. 10, 2007).
- Moore et al., "Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing B-cell lymphoma," *Blood*, Apr. 28, 2011, pp. 4542-4551, vol. 117, No. 17.
- Morris et al., "Pilot trial of unlabeled and indium-111-labeled anti-prostate-specific membrane antigen antibody J591 for castrate metastatic prostate cancer," *Clinical Cancer Research*, vol. 11, pp. 7454-7461 (2005).
- Neumaier et al., "Cloning of the genes for T84.66, and antibody that has a high specificity and affinity for carcinoembryonic antigen, and expression of chimeric human/mouse T84.66 genes in myeloma and Chinese hamster ovary cells," *Cancer Research*, 1990, vol. 50, pp. 2128-2134.
- Notice of Opposition to European Patent Application No. 0668777 filed Jul. 11, 2007 by BZL Biologics LLC.
- Notice of Opposition to European Patent Application No. 0956506 filed Dec. 1, 2006 by PSMA Development Company LLC.
- Office Action issued in U.S. Appl. No. 12/788,477, filed May 27, 2012 in 22 pages.

(56)

## References Cited

## OTHER PUBLICATIONS


- Olafsen et al., "Characterization of engineered anti-p185<sup>HER2</sup> (scFv-C<sub>H</sub>3)<sub>2</sub> antibody fragments (minibodies) for tumor targeting", *Protein Engineering, Design & Selection*, vol. 17 No. 4, pp. 315-323, Oxford University Press (2004).
- Olafsen et al., "Covalent disulfide-linked anti-CEA diabody allows site-specific conjugation and radiolabeling for tumor targeting applications," *Protein Eng. Des. Sel.*, Jan. 2004, pp. 21-27, vol. 17, No. 1.
- Olafsen et al., "ImmunoPET imaging of B-cell lymphoma using 124I-anti-CD20 scFv dimers (diabodies)," *Protein Eng. Des. Sel.*, Apr. 2010, pp. 243-249, vol. 23, No. 4.
- Olafsen et al., "Recombinant anti-CD20 antibody fragments for small-animal PET imaging of B-Cell lymphomas", *The Journal of Nuclear Medicine*, vol. 50 No. 9, pp. 1500-1508 (Sep. 2009).
- Olafsen et al., "Tunable pharmacokinetics: modifying the in vivo half-life of antibodies by directed mutagenesis of the Fc fragment", *Nature Protocols*, vol. 1 No. 4, pp. 2048-2060 (2006).
- Olson et al., "Clinical trials of cancer therapies targeting prostate-specific membrane antigen", *Reviews on Recent Clinical Trials*, vol. 2, pp. 182-190 (2007).
- Paul, W.E., "Fundamental Immunology," 3d ed., pp. 242, 282-295 1993.
- Preliminary Amendment filed on Dec. 21, 2011 in U.S. Appl. No. 12/788,477, filed May 27, 2012 in 9 pages.
- Raag et al., "Single-chain Fvs," *FASEB J.*, Jan. 1995, vol. 9, No. 1, pp. 73-80.
- Richstone et al., "Eradication of Prostate Cancer Xenografts by Immunoconjugates Targeting the Extracellular Domain of Prostate-Specific Membrane Antigen (PSMA)," *Proceedings of the American Society of Clinical Oncology*, vol. 19, abstract 1329, May 20, 2000.
- Rudikoff et al., "Single Amino Acid Substitution Altering Antigen-Binding Specificity," *Proc. Natl. Acad. Sci. USA*, Marcy 1982, pp. 1979-1983, vol. 79.
- Schlom, "Molecular Foundations of Oncology", Chapter 6, pp. 93-134, 1991.
- Schulke et al., "The Homodimer of Prostate-Specific Membrane Antigen is a Functional Target for Cancer Therapy," *PNAS*, 100 (22), pp. 12590-12595, Oct. 28, 2003.
- Shinnick et al., "Peptide-Elicited Protein-Reactive Antibodies in Molecular Biology and Medicine," *J. Invest. Dermatol.*, 83 (1 Suppl.): 112s-115s, Jul. 1984.
- Silver D A et al., "Prostate-specific membrane antigen expression in normal and malignant human tissues," *Clinical Cancer Research*, vol. 3, pp. 81-85, Jan. 1997.
- Sirk et al., "Site-specific, thiol-mediated conjugation of fluorescent probes to cysteine-modified diabodies targeting CD20 or HER2," *Dec. 2008*, pp. 2527-2534, vol. 19, No. 12.
- Slovin, "Targeting novel antigens for prostate cancer treatment: focus on prostate-specific membrane antigen", *NIH Public Access: Author Manuscript, Expert Opin Ther Targets*, vol. 9 No. 3, pp. 561-570 (Jun. 2005).
- Smith, S., "Technology evaluation: C242-DM1, ImmunoGem, Inc." *Current Opinion in Molecular Therapeutics*, 3(2):198-203, Apr. 2001.
- Stimmel et al., "Site-specific conjugation on serine → Cysteine variant monoclonal antibodies," *The Journal of Biological Chemistry*, Sep. 29, 2000, pp. 30445-30450, vol. 275, No. 39.
- Tai et al., "Targeting c-erbB-2 expressing tumors using single-chain Fv monomers and dimers," *Cancer Res.*, Dec. 1, 1995, pp. 5983s-5989s, vol. 55, No. 23 Suppl.
- Troyer J K et al., "Detection and characterization of the prostate specific membrane antigen (PSMA) in tissue extracts and body fluids," *Int. J. Cancer*, 62, pp. 552-558, (1995).
- Troyer, J.K., et al., "Location of Prostate-Specific Membrane Antigen in the LNCaP Prostate Carcinoma Cell Line," *The Prostate* 30, 1997, pp. 232-242.
- U.S. Appl. No. 10/690,990, filed Oct. 23, 2002.
- U.S. Appl. No. 12/788,477, filed May 27, 2012.
- Urva et al., "Physiologically based pharmacokinetic (PBPK) model for T.84.66, a monoclonal anti-CEA antibody," *Am. Assoc. Pharm. Sci.* 10 (Supp. 2), 2008, pp. 957.
- Vaidyanathan et al., "Evaluation of an anti-p 185<sup>HER2</sup> (scFv-C<sub>H</sub>2-C<sub>H</sub>2)<sub>2</sub> fragment following radioiodination using two different residualizing labels: SGMIB and IB-Mal-D-GEEK\*," *Nuclear Medicine and Biology*, 2009, pp. 671-680, vol. 36.
- Verhaar et al., "Technetium-99m radiolabeling using a phage-derived single-chain Fv with a C-terminal cysteine," *The Journal of Nuclear Medicine*, May 1996, pp. 868-872, vol. 37, No. 5.
- Veri et al., "Therapeutic control of B cell activation via recruitment of Fcγ receptor IIb (CD32B) inhibitory function with a novel bispecific antibody scaffold." *Arthritis Rheum.* 62.7 (Jul. 2010): 1933-43.
- Weiner, "An Overview of Monoclonal Antibody Therapy of Cancer," *Seminars Oncology*, vol. 26, No. 4, pp. 41-50, 1999.
- Whitlow et al., "Multivalent Fvs: characterization of single-chain Fv oligomers and preparation of a bispecific Fv," *Protein Engineering*, Aug. 1994, vol. 7, No. 8, pp. 1017-1026.
- Wong et al., "Pilot trial evaluating an <sup>125</sup>I-Labeled 80-Kilodalton engineered anticarcinoembryonic antigen antibody fragment (cT84.66 minibody) in patients with colorectal cancer," *Clinical Cancer Research*, vol. 10, pp. 5014-5021 (Aug. 1, 2004).
- Wu et al., "Antibodies for molecular imaging of cancer", *The Cancer Journal*, vol. 14 No. 3, pp. 191-197 (May/Jun. 2008).
- Wu et al. "Humanization of a Murine Monoclonal Antibody by Simultaneous Optimization of Framework and CDR Residues," *J. Mol. Biol.*, 294(1): 151-162, Nov. 19, 1999.
- Wu et al., "Antibodies and antimatter: The Resurgence of Immuno-PET", *The Journal of Nuclear Medicine*, vol. 50 No. 1, pp. 2-5 (Jan. 2009).
- Wu et al., "Anti-carcinoembryonic antigen (CEA) diabody for rapid tumor targeting and imaging," *Tumor Targeting*, 1999, pp. 47-58, vol. 4.
- Wu et al., "Arming antibodies: prospects and challenges for immunoconjugates", *Nature Biotechnology*, vol. 23 No. 9, pp. 1137-1146 (Sep. 2005).
- Wu et al., "High-resolution microPET imaging of carcino-embryonic antigen-positive xenografts by using a copper-64-labeled engineered antibody fragment," *Proc. Natl. Acad. Sci. USA*, 2000, pp. 8495-8500, vol. 97, No. 15.
- Wu et al., "Tumor localization of anti-CEA single-chain Fvs: Improved targeting by non-covalent dimers," *Immunotechnology*, 1996, pp. 21-36, vol. 2.
- Yazaki et al., "Mammalian expression and hollow fiber bioreactor production of recombinant anti-CEA diabody and minibody for clinical applications," *Journal of Immunological Methods*, 2001, pp. 195-208, vol. 253.
- Yazaki et al., "Tumor Targeting of Radiometal Labeled Anti-CEA Recombinant T84.66 Diabody and T84.66 Minibody: Comparison to Radioiodinated Fragments." *Bioconjugate Chem.* 12 (2001): 220-228.
- You et al., "Expression, purification, and characterization of a two domain carcinoembryonic antigen minigene (N-A3) in *Pichia pastoris* the essential role of the N-domain," *Anticancer Research*, 1998, pp. 3193-3202, vol. 18.
- Cheung, V. et al., "Ganglioside GD2 Specific Monoclonal Antibody 3F8: A Phase I Study in Patients With Neuroblastoma and Malignant Melanoma," *Journal of Clinical Oncology*, vol. 5, No. 9 (September), 1987, pp. 1430-1440.
- Lewis, D. et al., "Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies," *Cancer Immunology Immunotherapy*, (1993) 37:255-263.
- Morris, J. et al., "Pilot Trial of Unlabeled and Indium-111-Labeled Anti-Prostate-Specific Membrane Antigen Antibody J591 for Castrate Metastatic Prostate Cancer," *Clin Cancer Res* 2005;11:7454-7461. Published online Oct. 20, 2005.

\* cited by examiner







**FIG. 1**




**FIG. 2**



**FIG. 3**



**FIG. 4**



**FIG. 5**




FIG. 6




FIG. 7

## LIPMAN-PEARSON PROTEIN ALIGNMENT

KTUPLE: 2; GAP PENALTY: 4; GAP LENGTH PENALTY: 12

SEQ1(1>115)	SEQ2(1>125)	SIMILARITY	GAP	GAP	CONSENSUS
J591VH.PRO	MUVHIIA.PRO	INDEX	NUMBER	LENGTH	LENGTH
(1>115)	(1>125)	75.6	2	10	125

EVQLQQSGPELVKPGTSVRISCKTSGYTFTEYTI-HWVKQSHGKSLEWIGNINPNNGGTT  
EVQLQQSGPELVKPG:SV:ISCK:SGYTFY:Y : :WVKQS.GKSLEWIG:INP.NGGT:  
EVQLQQSGPELVKPGASVKISCKASGYTFDYYMNNWVKQSPGKSLEWIGDINPNNGGTS  
YNQKFEDKATLITVDKSSSTAYMELRSLTSEDSAVYYCAAG-----WNFDYWGGIT  
YNQKF.:KATLITVDKSSSTAYM:L.SLTSEDSAVYYCA G ..FDYWGGIT  
YNQKFKGKATLITVDKSSSTAYMQLSLTSEDSAVYYCARGYSSSYMAYYAFDYWGQGIT

LTVSS  
:TVSS  
VIVSS

FIG. 8






FIG. 9

ENZYMES: ALL 74 ENZYMES (NO FILTER):  
 SETTINGS: LINEAR, CERTAIN SITES ONLY, STANDARD GENETIC CODE




FIG. 10

LIPMAN-PEARSON PROTEIN ALIGNMENT  
KTUPLE: 2; GAP PENALTY: 4; GAP LENGTH PENALTY: 12

SEQ1(1>107)	SEQ2(1 > 111)	SIMILARITY	GAP	GAP	CONSENSUS
J591VK.PRO	MUVKV.PRO	INDEX	NUMBER	LENGTH	LENGTH
(1>107)	(1>109)	60.4	2	2	109

↓10 ↓20 ↓30 ↓40 ↓50  
NIVMTQSPKSMMSVGERVILTCKAS-ENVVTYVSWYQQKPEQSPKLLIYGASNRYTGVP  
:I MTQSP.S:S S:G:RVT:TC:AS ::: .Y::WYQQK. SPKLLIY AS. .:GVP  
DIQMTQSPSSLSASLGDRVTITCRASQDDISNYIINWYQQKPGGSEPKLLIYYASRIHSGVP  
↑10 ↑20 ↑30 ↑40 ↑50 ↑60  
↓60 ↓70 ↓80 ↓90 ↓100  
DRFTGSGSAIDFTLITSSVQAEDLADYHGGGYSY-PYTFGGGKLEIK  
.RF:GSGS:TD::LTIS:::ED:A.Y C QG : P TFGGGKLEIK  
SRFSGSGSGTDYSLTISNLEQEDIAITYFOQQNTLPPRTFGGGKLEIK  
↑70 ↑80 ↑90 ↑100

FIG. 11



## TREATMENT AND DIAGNOSIS OF CANCER

The present application is a continuation of U.S. patent application Ser. No. 11/481,344, filed Jul. 5, 2006 and now abandoned, which is a continuation of U.S. patent application Ser. No. 09/929,546, filed Aug. 13, 2001, now U.S. Pat. No. 7,163,680, which is a continuation of U.S. patent application Ser. No. 09/357,708, filed Jul. 20, 1999, now U.S. Pat. No. 6,770,450, which is a divisional of U.S. patent application Ser. No. 08/895,914, filed Jul. 17, 1997, now U.S. Pat. No. 6,136,311, which is a continuation-in-part of U.S. patent application Ser. No. 08/838,682, filed Apr. 9, 1997, now U.S. Pat. No. 6,107,090, which claims the benefit of U.S. Provisional Patent Application Ser. No. 60/016,976, filed May 6, 1996, and of U.S. Provisional Patent Application Ser. No. 60/022,125, filed Jul. 18, 1996, the entire contents of all of which are incorporated by reference herein.

## FIELD OF THE INVENTION

The present invention relates to the treatment and diagnosis of cancer with biological agents.

## BACKGROUND OF THE INVENTION

In spite of improved treatments for certain forms of cancer, it is still a leading cause of death in the United States. Since the chance for complete remission of cancer is, in most cases, greatly enhanced by early diagnosis, it is very desirable that physicians be able to detect cancers before a substantial tumor develops. However, the development of methods that permit rapid and accurate detection of many forms of cancers continues to challenge the medical community. One such illustrative form of cancer is prostate cancer.

Prostate cancer is the most common cancer in men with an estimated 317,000 cases in 1996 in the United States. It is the second leading cause of death among men who die from neoplasia with an estimated 40,000 deaths per year. Prompt detection and treatment is needed to limit mortality caused by prostate cancer.

## Detection of Prostate Cancer

When it metastasizes, prostatic cancer has a distinct predilection for bone and lymph nodes. Saitoh et al., "Metastatic Patterns of Prostatic Cancer. Correlation Between Sites And Number Of Organs Involved," *Cancer*, 54:3078-3084 (1984). At the time of clinical diagnosis, as many as 25% of patients have bone metastasis demonstrable by radionuclide scans. Murphy, G. P., et al., "The National Survey Of Prostate Cancer In The United States By The American College Of Surgeons," *J. Urol.*, 127:928-939 (1982). Accurate clinical evaluation of nodal involvement has proven to be difficult. Imaging techniques such as computed tomography ("CT") or magnetic resonance ("MR") imaging are unable to distinguish metastatic prostate cancer involvement of lymph nodes by criterion other than size (i.e., >1 cm). Therefore, by definition, these imaging modalities are inherently insensitive in the detection of small volume (<1 cm) disease as well as non-specific in the detection of larger volume adenopathy. A recent study assessed the accuracy of MR in patients with clinically localized prostate cancer. Rifkin et al., "Comparison Of Magnetic Resonance Imaging And Ultrasonography In Staging Early Prostate Cancer," *N. Engl. J. Med.*, 323: 621-626 (1990). In this study, 194 patients underwent an MR and 185 of these patients had a lymph node dissection. 23 (13%) patients had pathologically involved lymph nodes. MR was suspicious in only 1 of these 23 cases resulting in a sensitivity of 4%. Similar results have also been noted with

CT scans. Gasser et al., "MRI And Ultrasonography In Staging Prostate Cancer," *N. Engl. J. Med.* (Correspondence), 324(7):49-495 (1991).

The elevation of serum acid phosphatase activity in patients having metastasized prostate carcinoma was first reported by Gutman et al., *J. Clin. Invest* 17:473 (1938). In cancer of the prostate, prostatic acid phosphatase is released from the cancer tissue into the blood stream with the result that the total serum acid phosphatase level can be greatly increased above normal values. Numerous studies of this enzyme and its relation to prostatic cancer have been made since that time, e.g. Yam, *Amer. J. Med.* 56:604 (1974). However, the measurement of serum acid phosphatase is elevated in about 65-90 percent of patients having carcinoma of the prostate with bone metastasis; in about 30 percent of patients without roentgenological evidence of bone metastasis; and in about only 5-10 percent of patients lacking clinically demonstrable metastasis.

Prior art attempts to develop a specific test for prostatic acid phosphatase have met with only limited success, because techniques which rely on enzyme activity on a so-called "specific" substrate cannot take into account other biochemical and immunochemical differences among the many acid phosphatases which are unrelated to enzyme activity of prostate origin. In the case of isoenzymes, i.e. genetically defined enzymes having the same characteristic enzyme activity and a similar molecular structure but differing in amino acid sequences and/or content and, therefore, immunochemically distinguishable, it would appear inherently impossible to distinguish different isoenzyme forms merely by the choice of a particular substrate. It is, therefore, not surprising that none of these prior art methods is highly specific for the direct determination of prostatic acid phosphatase activity; e.g. see *Cancer* 5:236 (1952); *J. Lab. Clin. Med.* 82:486 (1973); *Clin. Chem. Acta.* 44:21 (1973); and *J. Physiol. Chem.* 356:1775 (1975).

In addition to the aforementioned problems of non-specificity which appear to be inherent in many of the prior art reagents employed for the detection of prostate acid phosphatase, there have been reports of elevated serum acid phosphatase associated with other diseases, which further complicates the problem of obtaining an accurate clinical diagnosis of prostatic cancer. For example, Tuchman et al., *Am. J. Med.* 27:959 (1959) noted that serum acid phosphatase levels appear to be elevated in patients with Gaucher's disease.

Due to the inherent difficulties in developing "specific" substrate for prostate acid phosphatase, several researchers have developed immunochemical methods for the detection of prostate acid phosphatase. However, the previously reported immunochemical methods have drawbacks of their own which have precluded their widespread acceptance. For example, Shulman et al., *Immunology* 93:474 (1964) described an immuno-diffusion test for the detection of human prostate acid phosphatase. Using antisera prepared from a prostatic fluid antigen obtained by rectal massage from patients with prostatic disease, no cross-reactivity precipitin line was observed in the double diffusion technique against extracts of normal kidney, testicle, liver, and lung. However, this method has the disadvantages of limited sensitivity, even with the large amounts of antigen employed, and of employing antisera which may cross-react with other, antigenically unrelated serum protein components present in prostatic fluid.

WO 79/00475 to Chu et. al. describes a method for the detection of prostatic acid phosphatase isoenzyme patterns associated with prostatic cancer which obviates many of the above drawbacks. However, practical problems are posed by

the need for a source of cancerous prostate tissue from which the diagnostically relevant prostatic acid phosphatase isoenzyme patterns associated with prostatic cancer are extracted for the preparation of antibodies thereto.

In recent years, considerable effort has been spent to identify enzyme or antigen markers for various types of malignancies with the view towards developing specific diagnostic reagents. The ideal tumor marker would exhibit, among other characteristics, tissue or cell-type specificity. Previous investigators have demonstrated the occurrence of human prostate tissue-specific antigens.

#### Treatment of Prostate Cancer

As described in W. J. Catalona, "Management of Cancer of the Prostate," *New Engl. J. Med.*, 331(15):996-1004 (1994), the management of prostate cancer can be achieved by watchful waiting, curative treatment, and palliation.

For men with a life expectancy of less than 10 years, watchful waiting is appropriate where low-grade, low-stage prostate cancer is discovered at the time of a partial prostatectomy for benign hyperplasia. Such cancers rarely progress during the first five years after detection. On the other hand, for younger men, curative treatment is often more appropriate.

Where prostate cancer is localized and the patient's life expectancy is 10 years or more, radical prostatectomy offers the best chance for eradication of the disease. Historically, the drawback of this procedure is that most cancers had spread beyond the bounds of the operation by the time they were detected. However, the use of prostate-specific antigen testing has permitted early detection of prostate cancer. As a result, surgery is less extensive with fewer complications. Patients with bulky, high-grade tumors are less likely to be successfully treated by radical prostatectomy.

After surgery, if there are detectable serum prostate-specific antigen concentrations, persistent cancer is indicated. In many cases, prostate-specific antigen concentrations can be reduced by radiation treatment. However, this concentration often increases again within two years.

Radiation therapy has also been widely used as an alternative to radical prostatectomy. Patients generally treated by radiation therapy are those who are older and less healthy and those with higher-grade, more clinically advanced tumors. Particularly preferred procedures are external-beam therapy which involves three dimensional, conformal radiation therapy where the field of radiation is designed to conform to the volume of tissue treated; interstitial-radiation therapy where seeds of radioactive compounds are implanted using ultrasound guidance; and a combination of external-beam therapy and interstitial-radiation therapy.

For treatment of patients with locally advanced disease, hormonal therapy before or following radical prostatectomy or radiation therapy has been utilized. Hormonal therapy is the main form of treating men with disseminated prostate cancer. Orchiectomy reduces serum testosterone concentrations, while estrogen treatment is similarly beneficial. Diethylstilbestrol from estrogen is another useful hormonal therapy which has a disadvantage of causing cardiovascular toxicity. When gonadotropin-releasing hormone agonists are administered testosterone concentrations are ultimately reduced. Flutamide and other nonsteroidal, anti-androgen agents block binding of testosterone to its intracellular receptors. As a result, it blocks the effect of testosterone, increasing serum testosterone concentrations and allows patients to remain potent—a significant problem after radical prostatectomy and radiation treatments.

Cytotoxic chemotherapy is largely ineffective in treating prostate cancer. Its toxicity makes such therapy unsuitable for elderly patients. In addition, prostate cancer is relatively resistant to cytotoxic agents.

#### Use of Monoclonal Antibodies in Prostate Cancer Detection and Treatment

Theoretically, radiolabeled monoclonal antibodies ("mAbs") offer the potential to enhance both the sensitivity and specificity of detecting prostatic cancer within lymph nodes and elsewhere. While many mAbs have previously been prepared against prostate related antigens, none of these mAbs were specifically generated with an imaging objective in mind. Nevertheless, the clinical need has led to evaluation of some of these mAbs as possible imaging agents. Vihko et al., "Radioimaging of Prostatic Carcinoma With Prostatic Acid Phosphatase—Specific Antibodies," *Biotechnology in Diagnostics*, 131-134 (1985); Babaian et al., "Radioimmunological Imaging of Metastatic Prostatic Cancer With 111-Indium-Labeled Monoclonal Antibody PAY 276," *J. Urol.*, 137:439-443 (1987); Leroy et al., "Radioimmunodetection Of Lymph Node Invasion In Prostatic Cancer. The Use Of Iodine 123 (123-I)-Labeled Monoclonal Anti-Prostatic Acid Phosphatase (PAP) 227 A F (ab') 2 Antibody Fragments In Vivo," *Cancer*, 64:1-5 (1989); Meyers et al., "Development Of Monoclonal Antibody Imaging Of Metastatic Prostatic Carcinoma," *The Prostate*, 14:209-220 (1989).

In some cases, the monoclonal antibodies developed for detection and/or treatment of prostate cancer recognize antigens specific to malignant prostatic tissues. Such antibodies are thus used to distinguish malignant prostatic tissue (for treatment or detection) from benign prostatic tissue. See U.S. Pat. No. 4,970,299 to Bazinet et al. and U.S. Pat. No. 4,902,615 to Freeman et al.

Other monoclonal antibodies react with surface antigens on all prostate epithelial cells whether cancerous or benign. See U.S. Pat. Nos. 4,446,122 and Re 33,405 to Chu et al., U.S. Pat. No. 4,863,851 to McEwan et al., and U.S. Pat. No. 5,055,404 to Ueda et al. However, the antigens detected by these monoclonal antibodies are present in the blood and, therefore, compete with antigens at tumor sites for the monoclonal antibodies. This causes background noise which makes the use of such antibodies inadequate for in vivo imaging. In therapy, such antibodies, if bound to a cytotoxic agent, could be harmful to other organs.

Horoszewicz et al., "Monoclonal Antibodies to a New Antigenic Marker in Epithelial Prostatic Cells and Serum of Prostatic Cancer Patients," *Anticancer Research*, 7:927-936 (1987) ("Horoszewicz") and U.S. Pat. No. 5,162,504 to Horoszewicz describe an antibody, designated 7E11, which recognizes prostate specific membrane antigen ("PSMA"). Israeli et al., "Molecular Cloning of a Complementary DNA Encoding a Prostate-specific Membrane Antigen," *Cancer Research*, 53:227-230 (1993) ("Israeli") describes the cloning and sequencing of PSMA and reports that PSMA is prostate-specific and shows increased expression levels in metastatic sites and in hormone-refractory states. Other studies have indicated that PSMA is more strongly expressed in prostate cancer cells relative to cells from the normal prostate or from a prostate with benign hyperplasia. Furthermore, PSMA is not found in serum (Troyer et al., "Detection and Characterization of the Prostate-Specific Membrane Antigen (PSMA) in Tissue Extracts and Body Fluids," *Int. J. Cancer*, 62:552-558 (1995)).

These characteristics make PSMA an attractive target for antibody mediated targeting for imaging and therapy of prostate cancer. Imaging studies using indium-labeled 7E11 have indicated that the antibody localizes quite well to both the

prostate and to sites of metastasis. In addition, 7E11 appears to have clearly improved sensitivity for detecting lesions compared to other currently available imaging techniques, such as CT and MR imaging or bone scan. Bander, "Current Status of Monoclonal Antibodies for Imaging and Therapy of Prostate Cancer," *Sem. In Oncology*, 21:607-612 (1994).

However, the use of 7E11 and other known antibodies to PSMA to mediate imaging and therapy has several disadvantages. First, PSMA is an integral membrane protein known to have a short intracellular tail and a long extracellular domain. Biochemical characterization and mapping (Troyer et al., "Biochemical Characterization and Mapping of the 7E11-C5.3 Epitope of the Prostate-specific Membrane Antigen," *Urol. Oncol.*, 1:29-37 (1995)) have shown that the epitope or antigenic site to which the 7E11 antibody binds is present on the intracellular portion of the molecule. Because antibody molecules do not, under normal circumstances, cross the cell membrane unless they bind to the extracellular portion of a molecule and become translocated intracellularly, the 7E11 antibody does not have access to its antigenic target site in an otherwise healthy, viable cell.

Consequently, imaging using 7E11 is limited to the detection of dead cells within tumor deposits. Additionally, the therapeutic use of the 7E11 antibody is limited, because only cells that are already dead or tissue containing a large proportion of dead cells can be effectively targeted.

Although the inadequacies and problems in the diagnosis and treatment of one particular type of cancer are the focus of the preceding discussion, prostate cancer is merely a representative model. The diagnosis and treatment of numerous other cancers have similar problems.

The present invention is directed to overcoming the deficiencies of prior art antibodies in diagnosing and treating prostate and other types of cancer.

#### SUMMARY OF THE INVENTION

One aspect of the present invention relates to a method of ablating or killing cancerous cells. The process involves providing a biological agent which, when contacted with an extracellular domain of prostate specific membrane antigen, recognizes the extracellular domain of prostate specific membrane antigen. These biological agents are contacted with vascular endothelial cells proximate to the cancerous cells under conditions effective to permit both binding of the biological agent to the vascular endothelial cells proximate to the cancerous cells and killing or ablating of the cancerous cells. The biological agent can be used alone or can be bound to a substance effective to kill or ablate the cancerous cells upon binding of the biological agent to vascular endothelial cells that are proximate to the cancerous cells.

In a particularly preferred embodiment of the method of ablating or killing cancerous cells in accordance with the present invention, the biological agent, when contacted with an extracellular domain of prostate specific membrane antigen, binds to and is internalized with the prostate specific membrane antigen of such cells. Preferred biological agents for use in the method of ablating or killing cancerous cells in accordance with the present invention are antibodies or binding portions thereof, probes, or ligands. The methods of the present invention are particularly useful in killing or ablating renal, urothelial, colon, rectal, lung, and breast cancerous cells and cancerous cells of metastatic adenocarcinoma to the liver.

Another aspect of the present invention relates to a method of detecting cancerous tissue in a biological sample. This method involves providing a biological agent which, when

contacted with an extracellular domain of prostate specific membrane antigen, binds to the extracellular domain of prostate specific membrane antigen. The biological agent is bound to a label effective to permit detection of vascular endothelial cells proximate to or within the cancerous tissue upon binding of the biological agent to the vascular endothelial cells proximate to or within the cancerous tissue. The biological sample is contacted with the biological agent having a label under conditions effective to permit binding of the biological agent to the vascular endothelial cells proximate to or within the cancerous tissue in the biological sample. The presence of cancerous tissue in the biological sample is detected by detection of the label.

In a particularly preferred embodiment of the method of detecting cancerous tissue in accordance with the present invention, the biological agent is one that, when contacted with an extracellular domain of prostate specific membrane antigen, binds to and is internalized with the prostate specific membrane antigen. Preferred biological agents for use in the method of detecting cancerous tissue in accordance with the present invention are antibodies or binding portions thereof, probes, or ligands. The method is especially useful in detecting renal, urothelial, colon, rectal, lung, and breast cancerous tissue and cancerous tissue of metastatic adenocarcinoma to the liver.

Still another aspect of the present invention relates to a method of ablating or killing normal, benign hyperplastic, and cancerous prostate epithelial cells. The process involves providing a biological agent which recognizes an extracellular domain of prostate specific membrane antigen. The biological agent can be used alone or can be bound to a substance effective to kill the cells upon binding of the biological agent to the cells. These biological agents are then contacted with the cells under conditions effective to permit both binding of the biological agent to the extracellular domain of the prostate specific membrane antigen and killing or ablating of the cells.

In a particularly preferred embodiment of the method of ablating or killing normal, benign hyperplastic, and cancerous prostate epithelial cells in accordance with the present invention, the biological agent binds to and is internalized with the prostate specific membrane antigen of such cells. Preferred biological agents for use in the method of ablating or killing normal, benign hyperplastic, and cancerous prostate epithelial cells in accordance with the present invention are antibodies or binding portions thereof, probes, or ligands.

Another aspect of the present invention relates to a method of detecting normal, benign hyperplastic, and cancerous prostate epithelial cells or portions thereof in a biological sample. This method involves providing a biological agent which binds to an extracellular domain of prostate specific membrane antigen. The biological agent is bound to a label effective to permit detection of the cells or portions thereof upon binding of the biological agent to the cells or portions thereof. The biological sample is contacted with the biological agent having a label under conditions effective to permit binding of the biological agent to the extracellular domain of the prostate specific membrane antigen of any of the cells or portions thereof in the biological sample. The presence of any cells or portions thereof in the biological sample is detected by detection of the label.

In a particularly preferred embodiment of the method of detecting normal, benign hyperplastic, and cancerous prostate epithelial cells in accordance with the present invention, the biological agent binds to and is internalized with the prostate specific membrane antigen of such cells. Preferred biological agents for use in the method of detecting normal, benign hyperplastic, and cancerous prostate epithelial cells in

accordance with the present invention are antibodies or binding portions thereof, probes, or ligands.

Another aspect of the present invention pertains to a biological agent that recognizes an extracellular domain of prostate specific membrane antigen. In a preferred embodiment, the isolated biological agent binds to and is internalized with the prostate specific membrane antigen. Preferred isolated biological agents which recognize an extracellular domain of prostate specific membrane antigen in accordance with the present invention are isolated antibodies or binding portions thereof, probes, or ligands. Hybridoma cell lines that produce monoclonal antibodies of these types are also disclosed.

The biological agents of the present invention recognize the extracellular domain of antigens of normal, benign hyperplastic, and cancerous prostate epithelial cells. Unlike the 7E11 antibody, which recognizes an epitope of prostate-associated antigens which are exposed extracellularly only after cell lysis, the biological agents of the present invention bind to antigenic epitopes which are extracellularly exposed in living prostate cells. Using the biological agents of the present invention, living, unfixed normal, benign hyperplastic, and cancerous prostate epithelial cells can be targeted, which makes treatment and diagnosis more effective. In a preferred embodiment for treating prostate cancer, the biological agents of the present invention also bind to and are internalized with the prostate specific membrane antigen, which permits the therapeutic use of intracellularly acting cytotoxic agents.

#### BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is an immuno-electron micrograph of gold-labeled monoclonal antibody J591 on the surface of LNCaP cells after incubation at 4° C.

FIG. 2 is an immuno-electron micrograph of LNCaP cells treated with gold-labeled monoclonal antibody J591 after 5 minutes incubation at 37° C.

FIG. 3 is an immuno-electron micrograph of LNCaP cells treated with gold-labeled monoclonal antibody J591 after 10 minutes incubation at 37° C.

FIG. 4 is an immuno-electron micrograph of LNCaP cells treated with gold-labeled monoclonal antibody J591 after 15 minutes incubation at 37° C.

FIG. 5 is an immuno-electron micrograph of LNCaP cells treated with gold-labeled monoclonal antibody J591 after 15 minutes at 37° C. showing J591 within endosomes.

FIG. 6 summarizes the sequencing strategy of the heavy chain of monoclonal antibody J591.

FIG. 7 shows the nucleotide sequence of the heavy chain of monoclonal antibody J591 (designated SEQ. ID. No. 1), the nucleotide sequence of the corresponding reverse, non-coding strand (designated SEQ. ID. No. 2), and the corresponding deduced amino acid sequences (designated SEQ. ID. Nos. 3, 4, and 5).

FIG. 8 is a comparison of the heavy chain of monoclonal antibody J591 (SEQ. ID. No. 8) with the consensus sequence for Mouse Heavy Chains Subgroup IIA (SEQ. ID. No. 20), (resulting comparison sequence SEQ. ID. No. 22).

FIG. 9 summarizes the sequencing strategy of the kappa light chain of monoclonal antibody J591.

FIG. 10 shows the nucleotide sequences of the kappa light chain of monoclonal antibody J591 (designated SEQ. ID. No. 9), the nucleotide sequence of the corresponding reverse, non-coding strand (designated SEQ. ID. No. 10), and the corresponding deduced amino acid sequence (designated SEQ. ID. Nos. 11, 12, and 13).

FIG. 11 is a comparison of the kappa light chain of monoclonal antibody J591 (SEQ. ID. No. 16) with the consensus sequence for Mouse Kappa Chains Subgroup V (SEQ. ID. No. 21), (resulting comparison sequence SEQ. ID. No. 23).

FIGS. 12A-12F are micrographs (250× magnification) showing the immunohistochemical reactivity of mAb J591 to neovasculature of various carcinomas.

#### DETAILED DESCRIPTION OF THE INVENTION

One aspect of the present invention relates to a method of ablating or killing normal, benign hyperplastic, and cancerous prostate epithelial cells. The process involves providing a biological agent, such as an antibody or binding portion thereof, probe, or ligand, which binds to an extracellular domain of prostate specific membrane antigen of (i.e., a portion of prostate specific membrane antigen which is external to) such cells. The biological agent can be used alone or can be bound to a substance effective to kill the cells upon binding of the biological agent to the cells. These biological agents are then contacted with the cells under conditions effective to permit both binding of the biological agent to the extracellular domain of the prostate specific membrane antigen and killing or ablating of the cells. In its preferred form, such contacting is carried out in a living mammal by administering the biological agent to the mammal under conditions effective to permit both binding of the biological agent to the extracellular domain of the prostate specific membrane antigen and killing or ablating of the cells. Such administration can be carried out orally or parenterally.

In a particularly preferred embodiment of the method of ablating or killing normal, benign hyperplastic, and cancerous prostate epithelial cells in accordance with the present invention, the biological agent binds to and is internalized with the prostate specific membrane antigen of such cells. Again, the biological agent can be used alone. Alternatively, the biological agent can be bound to a substance effective to kill the cells upon binding of the biological agent to prostate specific membrane antigen and upon internalization of the biological agent with the prostate specific membrane antigen.

The mechanism by which the biological agent is internalized with the prostate specific membrane antigen is not critical to the practice of the present invention. For example, the biological agent can induce internalization of the prostate specific membrane antigen. Alternatively, internalization of the biological agent can be the result of routine internalization of prostate specific membrane antigen.

The above-described biological agents (i.e., biological agents, such as an antibody or binding portion thereof, probe, or ligand which, when contacted with an extracellular domain of prostate specific membrane antigen, recognizes the extracellular domain of prostate specific membrane antigen and, preferably, is internalized therewith) can be used to ablate or kill cancerous cells. In this aspect of the present invention, the biological agent can be used alone or can be bound to a substance effective to kill the cancerous cells upon binding of the biological agent to vascular endothelial cells proximate thereto. These biological agents are contacted with vascular endothelial cells proximate to the cancerous cells. The contacting is carried out under conditions that are effective to permit binding of the biological agent to the vascular endothelial cells proximate to the cancerous cells and, in addition, that are effective to kill or ablate the cancerous cells. The mechanism by which the cancerous cells are killed or ablated is not critical to the practice of the present invention. For example, the cancerous cells can be killed or ablated directly by the biological agent as a consequence of their proximity to



the vascular endothelial cells to which the biological agent binds. Alternatively, the biological agent can kill, ablate, or otherwise change the properties of the vascular endothelial cells to which it binds so that blood flow to the cancerous cells proximate thereto is stopped or otherwise reduced, thereby causing the cancerous cells to be killed or ablated. Thus, the method of the present invention is particularly useful for killing or ablating vascular endothelial cells in cancerous tissue as well as the cancerous cells contained in cancerous tissue.

In a particularly preferred embodiment of the method of ablating or killing cancerous cells in accordance with the present invention, the biological agent employed is one that, when contacted with an extracellular domain of prostate specific membrane antigen, binds to and is internalized with the extracellular domain of prostate specific membrane antigen. The methods of the present invention are particularly useful to kill or ablate cancerous prostate epithelial cells as well as cancerous cells other than cancerous prostate epithelial cells. Examples of cancerous cells which are not cancerous prostate epithelial cells are renal, urothelial, colon, rectal, lung, and breast cancerous cells and cancerous cells of metastatic adenocarcinoma to the liver. Although the method of the present invention can be used to kill or ablate any cell which expresses an extracellular domain of prostate specific membrane antigen or a portion thereof or whose subsistence is dependent upon cells which express an extracellular domain of prostate specific membrane antigen or a portion thereof, the method of the present invention is particularly useful to kill or ablate cancerous cells, because the vascular endothelial cells supplying blood to cancerous tissues (e.g., tumors, collections of cancerous cells, or other cancerous masses) express an extracellular domain of prostate specific membrane antigen, irrespective of the type of cancer involved. In contrast, vascular endothelial cells supplying blood to normal tissues do not express an extracellular domain of prostate specific membrane antigen.

Another aspect of the present invention relates to a method of detecting normal, benign hyperplastic, and cancerous epithelial cells or portions thereof in a biological sample. This method involves providing a biological agent, such as an antibody or binding portion thereof, probe, or ligand, which binds to an extracellular domain of prostate specific membrane antigen of such cells. The biological agent is bound to a label effective to permit detection of the cells or portions (e.g., prostate specific membrane antigen or fragments thereof liberated from such normal, benign hyperplastic, and cancerous cells) thereof upon binding of the biological agent to the cells or portions thereof. The biological sample is contacted with the biological agent having a label under conditions effective to permit binding of the biological agent to the extracellular domain of the prostate specific membrane antigen of any of the cells or portions thereof in the biological sample. The presence of any cells or portions thereof in the biological sample is detected by detection of the label. In its preferred form, such contacting is carried out in a living mammal and involves administering the biological agent to the mammal under conditions effective to permit binding of the biological agent to the prostate specific membrane antigen of any of the cells or portions thereof in the biological sample. Again, such administration can be carried out orally or parenterally.

The method of the present invention can be used to screen patients for diseases associated with the presence of normal, benign hyperplastic, and cancerous epithelial cells or portions thereof. Alternatively, it can be used to identify the recurrence of such diseases, particularly when the disease is

localized in a particular biological material of the patient. For example, recurrence of prostatic disease in the prostatic fossa may be encountered following radical prostatectomy. Using the method of the present invention, this recurrence can be detected by administering a short range radiolabeled antibody to the mammal and then detecting the label rectally, such as with a transrectal detector probe.

Alternatively, the contacting step can be carried out in a sample of serum or urine or other body fluids, such as to detect the presence of PSMA in the body fluid. When the contacting is carried out in a serum or urine sample, it is preferred that the biological agent recognize substantially no antigens circulating in the blood other than PSMA. Since intact prostate cells do not excrete or secrete PSMA into the extracellular environment, detecting PSMA in serum, urine, or other body fluids generally indicates that prostate cells are being lysed. Thus, the biological agents and methods of the present invention can be used to determine the effectiveness of a prostate cancer treatment protocol by monitoring the level of PSMA in serum, urine or other body fluids.

In a particularly preferred embodiment of the method of detecting normal, benign hyperplastic, and cancerous prostate epithelial cells in accordance with the present invention, the biological agent, such as the antibody or binding portion thereof, probe, or ligand, binds to and is internalized with the prostate specific membrane antigen of such cells. Again, the biological agent is bound to a label effective to permit detection of the cells or portions thereof upon binding of the biological agent to and internalization of the biological agent with the prostate specific membrane antigen.

Another aspect of the present invention relates to a method of detecting cancerous tissue in a biological sample. This method involves providing the above-described biological agent (i.e., a biological agent, such as an antibody or binding portion thereof, probe, or ligand which, when contacted with an extracellular domain of prostate specific membrane antigen, recognizes the extracellular domain of prostate specific membrane antigen). The biological agent is bound to a label that is effective to permit detection of vascular endothelial cells proximate to or within the cancerous tissue upon binding of the biological agent to vascular endothelial cells proximate to or within the cancerous tissue. The biological sample is then contacted with the biological agent having a label. Contacting is carried out under conditions effective to permit binding of the biological agent to the vascular endothelial cells proximate to or within the cancerous tissue in the biological sample. The presence of cancerous cells or portions thereof in the biological sample is detected by detection of the label.

Rather than contacting the entire biological sample with the biological agent, it is contemplated that a portion of the biological sample can be used. For example, a tissue biopsy sample can be contacted with the biological agent to determine the presence of cancerous tissue in the tissue biopsy sample as well as in the larger biological sample from which it is taken. Alternatively, the biological agent can be contacted with a serum or urine sample to a certain whether any vascular endothelial cells expressing an extracellular domain of prostate specific membrane antigen are present therein. Since vascular endothelial cells expressing an extracellular domain of prostate specific membrane antigen are found in the vasculature of cancerous tissues but not in the vasculature of normal tissues, detection of the label in a serum or urine sample indicates the presence of cancerous tissue in the larger biological sample from which it is taken (e.g., a patient).

In a particularly preferred embodiment of the method of detecting cancerous tissues in accordance with the present

invention, the biological agent employed is one that, when contacted with an extracellular domain of prostate specific membrane antigen, binds to and is internalized with the prostate specific membrane antigen. The methods of the present invention can be used to detect cancerous prostate epithelial cells as well as cancerous tissues containing cancerous cells other than cancerous prostate epithelial cells. Examples of cancerous tissues containing cancerous cells other than cancerous prostate epithelial cells which can be detected with the methods of the present invention include renal, urothelial, colon, rectal, lung, and breast cancerous tissue and cancerous tissue of metastatic adenocarcinoma to the liver.

As indicated above, biological agents suitable for either killing, ablating, or detecting cancerous cells and normal, benign hyperplastic, and cancerous prostate epithelial cells include antibodies, such as monoclonal or polyclonal antibodies. In addition, antibody fragments, half-antibodies, hybrid derivatives, probes, and other molecular constructs may be utilized. These biological agents, such as antibodies, binding portions thereof, probes, or ligands, bind to extracellular domains of prostate specific membrane antigens or portions thereof in normal, benign hyperplastic, and cancerous prostate epithelial cells. As a result, when practicing the methods of the present invention to kill, ablate, or detect normal, benign hyperplastic, and cancerous prostate epithelial cells, the biological agents bind to all such cells, not only to cells which are fixed or cells whose intracellular antigenic domains are otherwise exposed to the extracellular environment. Consequently, binding of the biological agents is concentrated in areas where there are prostate epithelial cells, irrespective of whether these cells are fixed or unfixed, viable or necrotic. Additionally or alternatively, these biological agents, such as antibodies, binding portions thereof, probes, or ligands, bind to and are internalized with prostate specific membrane antigens or portions thereof in normal, benign hyperplastic, and cancerous prostate epithelial cells.

Monoclonal antibody production may be effected by techniques which are well-known in the art. Basically, the process involves first obtaining immune cells (lymphocytes) from the spleen of a mammal (e.g., mouse) which has been previously immunized with the antigen of interest either in vivo or in vitro. The antibody-secreting lymphocytes are then fused with (mouse) myeloma cells or transformed cells, which are capable of replicating indefinitely in cell culture, thereby producing an immortal, immunoglobulin-secreting cell line. The resulting fused cells, or hybridomas, are cultured, and the resulting colonies screened for the production of the desired monoclonal antibodies. Colonies producing such antibodies are cloned, and grown either in vivo or in vitro to produce large quantities of antibody. A description of the theoretical basis and practical methodology of fusing such cells is set forth in Kohler and Milstein, *Nature* 256:495 (1975), which is hereby incorporated by reference.

Mammalian lymphocytes are immunized by in vivo immunization of the animal (e.g., a mouse) with the protein or polypeptide of the present invention. Such immunizations are repeated as necessary at intervals of up to several weeks to obtain a sufficient titer of antibodies. Following the last antigen boost, the animals are sacrificed and spleen cells removed.

Fusion with mammalian myeloma cells or other fusion partners capable of replicating indefinitely in cell culture is effected by standard and well-known techniques, for example, by using polyethylene glycol ("PEG") or other fusing agents (See Milstein and Kohler, *Eur. J. Immunol.* 6:511 (1976), which is hereby incorporated by reference). This immortal cell line, which is preferably murine, but may also

be derived from cells of other mammalian species, including but not limited to rats and humans, is selected to be deficient in enzymes necessary for the utilization of certain nutrients, to be capable of rapid growth, and to have good fusion capability. Many such cell lines are known to those skilled in the art, and others are regularly described.

Procedures for raising polyclonal antibodies are also well known. Typically, such antibodies can be raised by administering the protein or polypeptide of the present invention subcutaneously to New Zealand white rabbits which have first been bled to obtain pre-immune serum. The antigens can be injected at a total volume of 100  $\mu$ l per site at six different sites. Each injected material will contain synthetic surfactant adjuvant pluronic polyols, or pulverized acrylamide gel containing the protein or polypeptide after SDS-polyacrylamide gel electrophoresis. The rabbits are then bled two weeks after the first injection and periodically boosted with the same antigen three times every six weeks. A sample of serum is then collected 10 days after each boost. Polyclonal antibodies are then recovered from the serum by affinity chromatography using the corresponding antigen to capture the antibody. Ultimately, the rabbits are euthenized with pentobarbital 150 mg/Kg IV. This and other procedures for raising polyclonal antibodies are disclosed in E. Harlow, et. al., editors, *Antibodies: A Laboratory Manual* (1988), which is hereby incorporated by reference.

In addition to utilizing whole antibodies, the processes of the present invention encompass use of binding portions of such antibodies. Such binding portions include Fab fragments, F(ab')<sub>2</sub> fragments, and Fv fragments. These antibody fragments can be made by conventional procedures, such as proteolytic fragmentation procedures, as described in J. Goding, *Monoclonal Antibodies: Principles and Practice*, pp. 98-118 (N.Y. Academic Press 1983), which is hereby incorporated by reference.

Alternatively, the processes of the present invention can utilize probes or ligands found either in nature or prepared synthetically by recombinant DNA procedures or other biological or molecular procedures. Suitable probes or ligands are molecules which bind to the extracellular domains of prostate specific membrane antigens identified by the monoclonal antibodies of the present invention. Other suitable probes or ligands are molecules which bind to and are internalized with prostate specific membrane antigens. Such probes or ligands can be, for example, proteins, peptides, lectins, or nucleic acid probes.

It is particularly preferred to use the monoclonal antibodies identified below in Table 1.

TABLE 1

Monoclonal Antibody Name	ATCC Designation for Hybridoma Cell Line
E99	HB-12101
J415	HB-12109
J533	HB-12127
J591	HB-12126

These antibodies can be used alone or as a component in a mixture with other antibodies or other biological agents to treat cancers or image cancerous tissues (particularly the vascular endothelial cells therein) or prostate epithelial cells with varying surface antigen characteristics.

Regardless of whether the biological agents are used for treatment or diagnosis, they can be administered orally, parenterally, subcutaneously, intravenously, intramuscularly, intraperitoneally, by intranasal instillation, by intracavitary or

intravesical instillation, intraocularly, intraarterially, intrale-  
sionally, or by application to mucous membranes, such as,  
that of the nose, throat, and bronchial tubes. They may be  
administered alone or with pharmaceutically or physiologi-  
cally acceptable carriers, excipients, or stabilizers, and can be  
in solid or liquid form such as, tablets, capsules, powders,  
solutions, suspensions, or emulsions.

The solid unit dosage forms can be of the conventional  
type. The solid form can be a capsule, such as an ordinary  
gelatin type containing the biological agent, such as an anti-  
body or binding portion thereof, of the present invention and  
a carrier, for example, lubricants and inert fillers such as,  
lactose, sucrose, or cornstarch. In another embodiment, these  
compounds are tableted with conventional tablet bases such  
as lactose, sucrose, or cornstarch in combination with binders  
like acacia, cornstarch, or gelatin, disintegrating agents such  
as, cornstarch, potato starch, or alginic acid, and a lubricant  
like stearic acid or magnesium stearate.

The biological agent of the present invention may also be  
administered in injectable dosages by solution or suspension  
of these materials in a physiologically acceptable diluent with  
a pharmaceutical carrier. Such carriers include sterile liquids  
such as water and oils, with or without the addition of a  
surfactant and other pharmaceutically and physiologically  
acceptable carrier, including adjuvants, excipients or stabiliz-  
ers. Illustrative oils are those of petroleum, animal, vegetable,  
or synthetic origin, for example, peanut oil, soybean oil, or  
mineral oil. In general, water, saline, aqueous dextrose and  
related sugar solution, and glycols such as, propylene glycol  
or polyethylene glycol, are preferred liquid carriers, particu-  
larly for injectable solutions.

For use as aerosols, the biological agent of the present  
invention in solution or suspension may be packaged in a  
pressurized aerosol container together with suitable propel-  
lants, for example, hydrocarbon propellants like propane,  
butane, or isobutane with conventional adjuvants. The materi-  
als of the present invention also may be administered in a  
non-pressurized form such as in a nebulizer or atomizer.

The biological agents may be utilized to detect cancerous  
tissues (particularly the vascular endothelial cells therein)  
and normal, benign hyperplastic, and cancerous prostate epi-  
thelial cells in vivo. This is achieved by labeling the biological  
agent, administering the labeled biological agent to a mam-  
mal, and then imaging the mammal.

Examples of labels useful for diagnostic imaging in accord-  
ance with the present invention are radio labels such as  $^{131}\text{I}$ ,  
 $^{111}\text{In}$ ,  $^{123}\text{I}$ ,  $^{99\text{m}}\text{Tc}$ ,  $^{32}\text{P}$ ,  $^{125}\text{I}$ ,  $^3\text{H}$ ,  $^{14}\text{C}$  and  $^{188}\text{Rh}$ , fluorescent  
labels such as fluorescein and rhodamine, nuclear magnetic  
resonance active labels, positron emitting isotopes detectable  
by a positron emission tomography ("PET") scanner, chemi-  
luminescers such as luciferin, and enzymatic markers such as  
peroxidase or phosphatase. Short-range radiation emitters,  
such as isotopes detectable by short-range detector probes,  
such as a transrectal probe, can also be employed. These  
isotopes and transrectal detector probes, when used in com-  
bination, are especially useful in detecting prostatic fossa  
recurrences and pelvic nodal disease. The biological agent  
can be labeled with such reagents using techniques known in  
the art. For example, see Wensel and Meares, *Radioimmu-  
noimaging and Radioimmunotherapy*, Elsevier, N.Y. (1983),  
which is hereby incorporated by reference, for techniques  
relating to the radiolabeling of antibodies. See also, D.  
Colcher et al., "Use of Monoclonal Antibodies as Radiophar-  
maceuticals for the Localization of Human Carcinoma  
Xenografts in Athymic Mice", *Meth. Enzymol.* 121: 802-816  
(1986), which is hereby incorporated by reference.

A radiolabeled biological agent of this invention can be  
used for in vitro diagnostic tests. The specific activity of a  
tagged biological agent, such as a tagged antibody, binding  
portion thereof, probe, or ligand, depends upon the half-life,  
the isotopic purity of the radioactive label, and how the label  
is incorporated into the biological agent. Table 2 lists several  
commonly-used isotopes, their specific activities and half-  
lives. In immunoassay tests, the higher the specific activity, in  
general, the better the sensitivity.

TABLE 2

Isotope	Specific Activity of Pure Isotope (Curies/mole)	Half-Life
$^{14}\text{C}$	$6.25 \times 10^4$	5720 years
$^3\text{H}$	$2.01 \times 10^4$	12.5 years
$^{35}\text{S}$	$1.50 \times 10^6$	87 days
$^{125}\text{I}$	$2.18 \times 10^6$	60 days
$^{32}\text{P}$	$3.16 \times 10^6$	14.3 days
$^{131}\text{I}$	$1.62 \times 10^7$	8.1 days

Procedures for labeling biological agents with the radioac-  
tive isotopes listed in Table 2 are generally known in the art.  
Tritium labeling procedures are described in U.S. Pat. No.  
4,302,438, which is hereby incorporated by reference. Iodi-  
nating, tritium labeling, and  $^{35}\text{S}$  labeling procedures espe-  
cially adapted for murine monoclonal antibodies are  
described by Goding, J. W. (supra, pp 124-126) and the ref-  
erences cited therein, which are hereby incorporated by ref-  
erence. Other procedures for iodinating biological agents,  
such as antibodies, binding portions thereof, probes, or  
ligands, are described by Hunter and Greenwood, *Nature*  
144:945 (1962), David et al., *Biochemistry* 13:1014-1021  
(1974), and U.S. Pat. Nos. 3,867,517 and 4,376,110, which  
are hereby incorporated by reference. Radiolabeling ele-  
ments which are useful in imaging include  $^{123}\text{I}$ ,  $^{131}\text{I}$ ,  $^{111}\text{In}$ ,  
and  $^{99\text{m}}\text{Tc}$ , for example. Procedures for iodinating biological  
agents are described by Greenwood, F. et al., *Biochem. J.*  
89:114-123 (1963); Marchalonis, J., *Biochem. J.* 113:299-  
305 (1969); and Morrison, M. et al., *Immunochemistry*, 289-  
297 (1971), which are hereby incorporated by reference. Pro-  
cedures for  $^{99\text{m}}\text{Tc}$ -labeling are described by Rhodes, B. et al.  
in Burchiel, S. et al. (eds.), *Tumor Imaging: The Radioimmu-  
nochemical Detection of Cancer*, New York: Masson 111-123  
(1982) and the references cited therein, which are hereby  
incorporated by reference. Procedures suitable for  $^{111}\text{In}$ -la-  
beling biological agents are described by Hnatowich, D. J. et  
al., *J. Immunol. Methods*, 65:147-157 (1983), Hnatowich, D. et  
al., *J. Applied Radiation*, 35:554-557 (1984), and Buckley, R.  
G. et al., *F.E.B.S.* 166:202-204 (1984), which are hereby  
incorporated by reference.

In the case of a radiolabeled biological agent, the biological  
agent is administered to the patient, is localized to the tumor  
bearing the antigen with which the biological agent reacts,  
and is detected or "imaged" in vivo using known techniques  
such as radionuclear scanning using e.g., a gamma camera or  
emission tomography. See e.g., A. R. Bradwell et al., "Devel-  
opments in Antibody Imaging", *Monoclonal Antibodies for  
Cancer Detection and Therapy*, R. W. Baldwin et al., (eds.),  
pp. 65-85 (Academic Press 1985), which is hereby incorpo-  
rated by reference. Alternatively, a positron emission tran-  
saxial tomography scanner, such as designated Pet VI located  
at Brookhaven National Laboratory, can be used where the  
radiolabel emits positrons (e.g.,  $^{11}\text{C}$ ,  $^{18}\text{F}$ ,  $^{15}\text{O}$ , and  $^{13}\text{N}$ ).

Fluorophore and chromophore labeled biological agents  
can be prepared from standard moieties known in the art.  
Since antibodies and other proteins absorb light having wave-

lengths up to about 310 nm, the fluorescent moieties should be selected to have substantial absorption at wavelengths above 310 nm and preferably above 400 nm. A variety of suitable fluorescers and chromophores are described by Stryer, *Science*, 162:526 (1968) and Brand, L. et al., *Annual Review of Biochemistry*, 41:843-868 (1972), which are hereby incorporated by reference. The biological agents can be labeled with fluorescent chromophore groups by conventional procedures such as those disclosed in U.S. Pat. Nos. 3,940,475, 4,289,747, and 4,376,110, which are hereby incorporated by reference.

One group of fluorescers having a number of the desirable properties described above are the xanthene dyes, which include the fluoresceins derived from 3,6-dihydroxy-9-henylxanthhydrol and resamines and rhodamines derived from 3,6-diamino-9-phenylxanthhydrol and lissamine rhodamine B. The rhodamine and fluorescein derivatives of 9-o-carboxyphenylxanthhydrol have a 9-o-carboxyphenyl group. Fluorescein compounds having reactive coupling groups such as amino and isothiocyanate groups such as fluorescein isothiocyanate and fluorescamine are readily available. Another group of fluorescent compounds are the naphthylamines, having an amino group in the  $\alpha$  or  $\beta$  position.

Biological agents can be labeled with fluorochromes or chromophores by the procedures described by Goding, J. (supra, pp 208-249). The biological agents can be labeled with an indicating group containing the NMR-active  $^{19}\text{F}$  atom, or a plurality of such atoms inasmuch as (i) substantially all of naturally abundant fluorine atoms are the  $^{19}\text{F}$  isotope and, thus, substantially all fluorine-containing compounds are NMR-active; (ii) many chemically active polyfluorinated compounds such as trifluoroacetic anhydride are commercially available at relatively low cost, and (iii) many fluorinated compounds have been found medically acceptable for use in humans such as the perfluorinated polyethers utilized to carry oxygen as hemoglobin replacements. After permitting such time for incubation, a whole body NMR determination is carried out using an apparatus such as one of those described by Pykett, *Scientific American*, 246:78-88 (1982), which is hereby incorporated by reference, to locate and image cancerous tissues (particularly the vascular endothelial cells therein) and prostate epithelial cells.

In cases where it is important to distinguish between regions containing live and dead prostate epithelial cells or to distinguish between live and dead prostate epithelial cells, the antibodies of the present invention (or other biological agents of the present invention), labeled as described above, can be coadministered along with an antibody or other biological agent which recognizes only living or only dead prostate epithelial cells labeled with a label which can be distinguished from the label used to label the subject antibody. By monitoring the concentration of the two labels at various locations or times, spatial and temporal concentration variations of living and dead normal, benign hyperplastic, and cancerous prostate epithelial cells can be ascertained. In particular, this method can be carried out using the labeled antibodies of the present invention, which recognize both living and dead epithelial prostate cells, and labeled 7E11 antibodies, which recognize only dead epithelial prostate cells.

The biological agents can also be utilized to kill or ablate cancerous cells and normal, benign hyperplastic, and cancerous prostate epithelial cells in vivo. This involves using the biological agents by themselves or with a cytotoxic drug to which the biological agents of the present invention (i.e., biological agents recognizing normal, benign hyperplastic, and cancerous prostate epithelial cells) are bound. This involves administering the biological agents bonded to a cyto-

toxic drug to a mammal requiring such treatment. In the case of normal, benign hyperplastic, and cancerous prostate epithelial cells, since the biological agents recognize prostate epithelial cells, any such cells to which the biological agents bind are destroyed. Although such administration may destroy normal prostate epithelial cells, this is not problematic, because the prostate is not required for life or survival. Although the prostate may indirectly contribute to fertility, this is not likely to be a practical consideration in patients receiving the treatment of the present invention. In the case of cancerous tissues, since the biological agents recognize vascular endothelial cells that are proximate to cancerous cells, binding of the biological agent/cytotoxic drug complex to these vascular endothelial cells destroys them, thereby cutting off the blood flow to the proximate cancerous cells and, thus, killing or ablating these cancerous cells. Alternatively, the biological agents, by virtue of their binding to vascular endothelial cells that are proximate to cancerous cells, are localized proximate to the cancerous cells. Thus, by use of suitable biological agents (including those containing substances effective to kill cells nondiscriminatingly but only over a short range), cells in cancerous tissue (including cancerous cells) can be selectively killed or ablated.

The biological agents of the present invention may be used to deliver a variety of cytotoxic drugs including therapeutic drugs, a compound emitting radiation, molecules of plants, fungal, or bacterial origin, biological proteins, and mixtures thereof. The cytotoxic drugs can be intracellularly acting cytotoxic drugs, such as short-range radiation emitters, including, for example, short-range, high-energy  $\alpha$ -emitters.

Enzymatically active toxins and fragments thereof are exemplified by diphtheria toxin A fragment, nonbinding active fragments of diphtheria toxin, exotoxin A (from *Pseudomonas aeruginosa*), ricin A chain, abrin A chain, modeccin A chain,  $\alpha$ -sarin, certain *Aleurites fordii* proteins, certain Dianthin proteins, *Phytolacca americana* proteins (PAP, PAPII and PAP-S), *Morodica charantia* inhibitor, curcumin, crotonin, *Saponaria officinalis* inhibitor, gelonin, mitogillin, restrictocin, phenomycin, and enomycin, for example. Procedures for preparing enzymatically active polypeptides of the immunotoxins are described in WO84/03508 and WO85/03508, which are hereby incorporated by reference. Certain cytotoxic moieties are derived from adriamycin, chlorambucil, daunomycin, methotrexate, neocarzinostatin, and platinum, for example.

Procedures for conjugating the biological agents with the cytotoxic agents have been previously described. Procedures for conjugating chlorambucil with antibodies are described by Flechner, I., *European Journal of Cancer*, 9:741-745 (1973); Ghose, T. et al., *British Medical Journal*, 3:495-499 (1972); and Szekerke, M., et al., *Neoplasia*, 19:211-215 (1972), which are hereby incorporated by reference. Procedures for conjugating daunomycin and adriamycin to antibodies are described by Hurwitz, E. et al., *Cancer Research*, 35:1175-1181 (1975) and Amon, R. et al. *Cancer Surveys*, 1:429-449 (1982), which are hereby incorporated by reference. Procedures for preparing antibody-ricin conjugates are described in U.S. Pat. No. 4,414,148 and by Osawa, T., et al. *Cancer Surveys*, 1:373-388 (1982) and the references cited therein, which are hereby incorporated by reference. Coupling procedures as also described in EP 86309516.2, which is hereby incorporated by reference.

In a particularly preferred embodiment of the present invention, especially well-suited for killing or ablating normal, benign hyperplastic, and cancerous prostate epithelial cells, a first biological agent is conjugated with a prodrug which is activated only when in close proximity with a pro-

drug activator. The prodrug activator is conjugated with a second biological agent according to the present invention, preferably one which binds to a non-competing site on the prostate specific membrane antigen molecule. Whether two biological agents bind to competing or non-competing binding sites can be determined by conventional competitive binding assays. For example, monoclonal antibodies J591, J533, and E99 bind to competing binding sites on the prostate specific membrane antigen molecule. Monoclonal antibody J415, on the other hand, binds to a binding site which is non-competing with the site to which J591, J533, and E99 bind. Thus, for example, the first biological agent can be one of J591, J533, and E99, and the second biological agent can be J415. Alternatively, the first biological agent can be J415, and the second biological agent can be one of J591, J533, and E99. Drug-prodrug pairs suitable for use in the practice of the present invention are described in Blakely et al., "ZD2767, an Improved System for Antibody-directed Enzyme Prodrug Therapy That Results in Tumor Regressions in Colorectal Tumor Xenografts," *Cancer Research*, 56:3287-3292 (1996), which is hereby incorporated by reference.

Alternatively, the biological agent can be coupled to high energy radiation emitters, for example, a radioisotope, such as  $^{131}\text{I}$ , a  $\gamma$ -emitter, which, when localized at the tumor site, results in a killing of several cell diameters. See, e.g., S. E. Order, "Analysis, Results, and Future Prospective of the Therapeutic Use of Radiolabeled Antibody in Cancer Therapy", *Monoclonal Antibodies for Cancer Detection and Therapy*, R. W. Baldwin et al. (eds.), pp 303-316 (Academic Press 1985), which is hereby incorporated by reference. Other suitable radioisotopes include  $\alpha$ -emitters, such as  $^{212}\text{Bi}$ ,  $^{213}\text{Bi}$ , and  $^{211}\text{At}$ , and  $\beta$ -emitters, such as  $^{186}\text{Re}$  and  $^{90}\text{Y}$ . Radiotherapy is expected to be particularly effective, because prostate epithelial cells and vascular endothelial cells within cancers are relatively radiosensitive.

Where the biological agents are used alone to kill or ablate cancerous cells or prostate epithelial cells, such killing or ablation can be effected by initiating endogenous host immune functions, such as complement-mediated or antibody-dependent cellular cytotoxicity.

The biological agent of the present invention can be used and sold together with equipment, as a kit, to detect the particular label.

Biological agents of the present invention can be used in conjunction with other therapeutic treatment modalities. Such other treatments include surgery, radiation, cryosurgery, thermotherapy, hormone treatment, chemotherapy, vaccines, and other immunotherapies.

Also encompassed by the present invention is a method of killing or ablating which involves using the biological agents for prophylaxis. For example, these materials can be used to prevent or delay development or progression of prostate or other cancers.

Use of the therapeutic methods of the present invention to treat prostate and other cancers has a number of benefits. Since the biological agents according to the present invention only target cancerous cells (such as cells of cancerous tissues containing vascular endothelial cells) and prostate epithelial cells, other tissue is spared. As a result, treatment with such biological agents is safer, particularly for elderly patients. Treatment according to the present invention is expected to be particularly effective, because it directs high levels of biological agents, such as antibodies or binding portions thereof, probes, or ligands, to the bone marrow and lymph nodes where prostate cancer metastases and metastases of many other cancers predominate. Moreover, the methods of the present invention are particularly well-suited for treating

prostate cancer, because tumor sites for prostate cancer tend to be small in size and, therefore, easily destroyed by cytotoxic agents. Treatment in accordance with the present invention can be effectively monitored with clinical parameters, such as, in the case of prostate cancer, serum prostate specific antigen and/or pathological features of a patient's cancer, including stage, Gleason score, extracapsular, seminal, vesicle or perineural invasion, positive margins, involved lymph nodes, etc. Alternatively, these parameters can be used to indicate when such treatment should be employed.

Because the biological agents of the present invention bind to living prostate cells, therapeutic methods for treating prostate cancer using these biological agents are much more effective than those which target lysed prostate cells. For the same reasons, diagnostic and imaging methods which determine the location of living normal, benign hyperplastic, or cancerous prostate epithelial cells (as well as vascular endothelial cells within cancers) are much improved by employing the biological agents of the present invention. In addition, the ability to differentiate between living and dead prostate cells can be advantageous, especially to monitor the effectiveness of a particular treatment regimen.

Hybridomas E99, J415, J533, and J591 have been deposited pursuant to, and in satisfaction of, the requirements of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure with the American Type Culture Collection ("A.T.C.C.") at 12301 Parklawn Drive, Rockville, Md. 20852. Hybridoma E99 was deposited on May 2, 1996, and received A.T.C.C. Designation Number HB-12101. Hybridoma J415 was deposited on May 30, 1996, and received A.T.C.C. Designation Number HB-12109. Hybridomas J533 and J591 were deposited on Jun. 6, 1996, and received A.T.C.C. Designation Numbers HB-12127 and HB-12126, respectively.

The present invention is further illustrated by the following examples.

## EXAMPLES

### Example 1

#### Human Tissues

Fresh specimens of benign and malignant tissues were obtained from the Department of Pathology of New York Hospital Cornell University Medical Center ("NYH-CUMC"),

### Example 2

#### Tissue Culture

Cultured cell lines of human cancers were obtained from the Laboratory of Urological Oncology of NYH-CUMC. The prostate cancer cell lines PC-3 (Mickey, D. D., et al., "Characterization Of A Human Prostate Adenocarcinoma Cell Line (DU145) As A Monolayer Culture And As A Solid

Tumor In Athymic Mice," *Prog. Clin. Biol. Res.*, 37:67-84 (1980), which is hereby incorporated by reference), DU-145 (Mickey, D. D., et al., "Characterization Of A Human Prostate Adenocarcinoma Cell Line (DU145) As A Monolayer Culture And As A Solid Tumor In Athymic Mice," *Prog. Clin. Biol. Res.*, 37:67-84 (1980), which is hereby incorporated by reference), and LNCaP (Horszewicz, J. S., et al., "LNCaP Model Of Human Prostatic Carcinoma," *Cancer Res.*, 43:1809-1818 (1983), which is hereby incorporated by reference) were obtained from the American Type Culture Collec-

tion (Rockville, Md.). Hybridomas were initially cloned in RPMI-1640 medium supplemented with 10% FCS, 0.1 mM nonessential amino acids, 2 mM L-glutamine, 100 units/ml of penicillin, 100 ug/ml of streptomycin and HAT medium (GIBCO, Grand Island, N.Y.). Subclones were cultured in the same medium without aminopterin.

### Example 3

#### Preparation of Mouse Monoclonal Antibodies

Female BALB/c mice were immunized intraperitoneally with LNCaP ( $6 \times 10^6$  cells) three times at 2 week intervals. A final intraperitoneal booster immunization was administered with fresh prostate epithelial cells which had been grown in vitro. Three days later, spleen cells were fused with SP-2 mouse myeloma cells utilizing standard techniques (Ueda, R., et al., "Cell Surface Antigens Of Human Renal Cancer Defined By Mouse Monoclonal Antibodies: Identification Of Tissue-Specific Kidney Glycoproteins," *Proc. Natl. Acad. Sci. USA*, 78:5122-5126 (1981), which is hereby incorporated by reference). Supernatants of the resulting clones were screened by rosette and complement cytotoxicity assays against viable LNCaP. Clones which were positive by these assays were screened by immunochemistry vs normal kidney, colon, and prostate. Clones which were LNCaP<sup>+</sup>/NmlKid<sup>-</sup>/colon<sup>-</sup>/prostate<sup>+</sup> were selected and subcloned 3 times by limiting dilution. The immunoglobulin class of cultured supernatant from each clone was determined by immunodiffusion using specified rabbit antisera (Calbiochem, San Diego, Calif.). mAbs were purified using the MAPS-II kit (Bio-Rad, Richmond, Calif.).

### Example 4

#### Biotinylation of m-Abs

Purified m-Abs were dialyzed in 0.1 M NaHCO<sub>3</sub> for 2 hours. One ml of mAb at 1 mg/ml was mixed with 0.1 ml of biotinamidocaproate N-hydroxysuccinamide ester (Sigma) in dimethylsulfoxide (1 mg/ml) and stirred for 4 hours at room temperature. Unbound biotin was removed by dialysis against phosphate buffered saline ("PBS").

### Example 5

#### Immunohistochemical Staining of Prostate Tissues

Cryostat sections of prostate tissues were placed inside rings of Falcon 3034 plate covers (Becton-Dickenson, Lincoln Park, N.J.) previously coated with 0.45% gelatin solution as described in Marusich, M. F., "A Rapid Method For Processing Very Large Numbers Of Tissue Sections For Immunohistochemical Hybridoma Screening," *J. Immunol. Methods*, 111:143-145 (1988), which is hereby incorporated by reference. Plates were stored at -80° C. Cryostat sections were fixed with 2% paraformaldehyde in PBS for 10 min at room temperature, and, after washing with PBS, endogenous peroxidase activity was blocked by treatment with 0.3% hydrogen peroxide in PBS for 10 min at room temperature. After sections were incubated with 2% BSA in PBS for 20 min, mAbs were added for 60 min at room temperature. Slides were extensively washed with PBS and incubated with peroxidase-conjugated rabbit anti-mouse Ig (DAKO Corp., Santa Barbara, Calif.) diluted 1:100 in 10% normal human

serum in PBS for 60 min at room temperature. After a diaminobenzidine reaction, sections were counterstained with hematoxylin.

### Example 6

#### Serological Analysis

The anti-mouse immunoglobulin mixed hemadsorption assay was performed as described in Ueda, R., et al., "Cell Surface Antigens Of Human Renal Cancer Defined By Mouse Monoclonal Antibodies: Identification Of Tissue-Specific Kidney Glycoproteins," *Proc. Natl. Acad. Sci. USA*, 78:5122-5126 (1981), which is hereby incorporated by reference. To prepare the indicator cells, anti-mouse Ig (DAKO Corp.) was conjugated to type 0 human RBC using 0.01% chromium chloride. Serological assays were performed on cells previously plated in Terasaki plates (Nunc, Denmark). Antibodies were incubated with target cells at room temperature for 1 hour. Target cells were then washed, and indicator cells added for 1 hour.

### Example 7

#### Immunoprecipitation

LNCaP cells ( $2 \times 10^7$ ) were biotinylated with biotin-NHSS (at final concentration of 5 mM) for 30 minutes on ice. After washing, the biotinylated cells were resuspended in 1 ml lysis buffer (20 mM Tris/HCl pH 8.0, 1 mM EDTA, 1 mM PMSF, 1% triton X-100) for 30 min on ice. The suspension was centrifuged at 1500 g x 100 min at 4° C., and the supernatant was centrifuged at 12,000 rpm x 15 min at 4° C. The resulting lysate was preabsorbed with rabbit or goat anti-mouse IgG-coated pansorbin for 1 hour at 4° C. The pre-absorbed lysate was incubated with the mAb overnight at 4° C. Rabbit or goat anti-mouse Ig-coated agarose beads were added for 2 hours at 4° C. and then washed. The beads were resuspended in Tris-base/NaCl, added to sample buffer with 2-mercaptoethanol, and boiled for 5 min. After centrifuging, the supernatant was run on an SDS-PAGE 12% gel. The gel was transferred to a nitrocellulose membrane which was blocked and stained with streptavidin-peroxidase. The membrane was developed with diaminobenzidine ("DAB").

Sequential immunoprecipitation was similar except that the lysate was initially pre-cleared with one mAb overnight at 4° C. A second mAb was then used to immunoprecipitate the pre-cleared lysate.

Approximately 2000 clones were screened, of which four clones were selected as described in Example 3, above. After subcloning, supernatants from the 4 hybridomas, E99, J415, J533, and J591, were assayed by immunofluorescence against viable (i.e. unfixed) LNCaP, immunoprecipitation, and sequential immunoprecipitation to confirm reactivity to PSMA.

The immunofluorescence study using the LNCaP target cell (described originally in Horoszewicz, which is hereby incorporated by reference, to make the 7E11 antibody and the prototype cell line for expression for PSMA) shows that E99 antibody binds to and renders viable LNCaP cells immunofluorescent. This is in contrast to the 7E11 antibody, which, as noted originally in Horoszewicz, which is hereby incorporated by reference, gives only poor or no binding to viable LNCaP cells but exhibits strong binding once the cells are fixed (killed).

21

The reactivities of the four mAbs with normal human tissues were examined immunohistochemically; these results are presented in Table 3.

TABLE 3

Reactivity of mAbs with human normal tissues by indirect immunoperoxidase staining				
Tissues	E99 ( $\gamma_3$ )	J415 ( $\gamma_3$ )	J533 ( $\gamma_3$ )	J591 ( $\gamma_3$ )
Prostate*	●	●	●	●
Kidney	○	○	○	○
Glomerulus	■	■	■	■
Prox. Tubule	○	○	○	○
Ureter	○	○	○	○
Bladder	○	○	○	○
Testis	○	○	○	○
Uterus	○	○	○	○
Esophagus	○	○	○	○
Small Intestine	○	○	○	○
Stomach	○	○	○	○
Colon	○	○	○	○
Spleen	○	○	○	○
Thyroid	○	○	○	○
Lung	○	○	○	○
Pancreas	○	○	○	○
Liver	○	○	○	○
*BPH	0-3 <sup>+</sup>	0-3 <sup>+</sup>	0-4 <sup>+</sup>	0-4 <sup>+</sup>
*Prostate Cancer	0-3 <sup>+</sup>	0-3 <sup>+</sup>	0-4 <sup>+</sup>	0-4 <sup>+</sup>
*LNCaP (scid)	3 <sup>+</sup>	3 <sup>+</sup>	4 <sup>+</sup>	4 <sup>+</sup>
*LuCaP (scid)	0-2 <sup>+</sup>	0-2 <sup>+</sup>	0-3 <sup>+</sup>	0-3 <sup>+</sup>

● - positive;  
■ - weak, heterogeneous;  
○ - negative

The above sequential Immunoprecipitation study showed that 7E11, E99, J415, J533, and J591 bind to the same molecule, i.e. PSMA.

## Example 8

## Western Blot Analysis

To confirm that antibodies E99, J415, J533, and J591 precipitate an identical band to the 7E11 antibody (i.e., PSMA), Western Blot analyses were performed. Seminal plasma (400  $\mu$ g/lane) or LNCaP lysate were loaded into lanes of 12% SDS-PAGE gels. After electrophoresis, the gels are transferred to nitrocellulose membranes. The membranes were blocked with 5% dry milk/Tris-buffered saline-tween 20 ("TBST") for 60 min at room temperature. After washing, the membranes were incubated with primary mAb for 60 min at room temperature. After repeat washing, the membranes were incubated with sheep anti-mouse-Ig-peroxidase 1/5000 in 5% dry milk/TBST for 60 min at room temperature. After repeat washing, the membranes were developed using a chemiluminescent tag designated "ECL" (Amersham Life Sciences, International, Arlington Heights, Ill.) according to the manufacturer's directions. The results of the Western Blot experiment are presented in Table 4.

TABLE 4

Western blot data					
Sample	7E11	E99	J415	J533	J591
Prostatic (seminal) fluid	100 KD band	100 KD band	100 KD band	100 KD band	100 KD band

22

TABLE 4-continued

Western blot data					
Sample	7E11	E99	J415	J533	J591
LNCaP cell lysate	100 KD & 200 KD bands	100 KD & 200 KD bands	100 KD & 200 KD bands	100 KD & 200 KD bands	100 KD & 200 KD bands

## Example 9

## mAb Reactivity to External Domain of PSMA

To confirm cell surface (external) expression of the detected PSMA, fresh, viable LNCaP cells were tested, without fixation, in vitro, by immunofluorescence. LNCaP cells were washed and incubated with mAb for 1 hour at room temperature and then with a rabbit anti-mouse Ig-fluorescein (DAKO Corp., Santa Barbara, Calif.). Wells were read with a fluorescent microscope. Negative control consisted of an isotype-matched irrelevant mAb, while an anti-class I MHC mAb served as a positive control.

Immunofluorescence and rosette assay results are presented in Table 5.

TABLE 5

Comparison of 7E11 with new mAbs					
LNCaP Viable Cells	7E11	E99	J415	J533	J591
Immunofluorescence	neg	3+	3+	4+	4+
Rosette assay	neg	+	+	+	+
LNCaP-fixed	+++	++++	+++	++	+++

## Example 10

## Competition Studies

A competition study was carried out to determine whether J591, J533, E99, and J415 detected the same or different antigenic sites (epitopes) of the prostate specific membrane antigen molecule using the following procedure.

Plates were coated with LNCaP cell line lysate as a source of prostate specific membrane antigen and washed to remove unbound material. "Cold" (unlabeled) monoclonal antibody was incubated on the plate for 1 hour at room temperature to allow binding to its antigenic site. Subsequently, a second monoclonal antibody, labeled either with biotin or  $^{125}$ I, was added for an additional hour. Plates were washed to remove unbound material. The amount of the second monoclonal antibody bound to the prostate specific membrane antigen-coated plate was determined either by avidin-alkaline phosphatase in an enzyme-linked immunoassay (in the case of biotin-labeled second monoclonal antibody) or by physically counting the well in a gamma counter (in the case of  $^{125}$ I-labeled second monoclonal antibody). Controls consisted of using the same monoclonal antibody both cold and labeled to define "100% competition" or using monoclonal antibody to a totally different molecule (e.g., monoclonal antibody I-56, which detects inhibin, a prostate related protein different from prostate specific membrane antigen) to define "0% competition".

The results indicated that J591, J533, and E99 each interfere, compete, or block binding of one another but do not block binding of J415 and vice versa. 7E11/CYT356, known to bind PSMA at a different (intracellular) site, did not block any of J591, J533, E99, or J415.

Having pairs of monoclonal antibodies which bind to non-competing sites permits development of antibody sandwich assays for detecting soluble antigens, such as solubilized prostate specific membrane antigen or fragment thereof, in, for example, body fluids. For example, the antigen (e.g., prostate specific membrane antigen or a fragment thereof) could be "captured" from body fluid with J591 and, in another step, detected by labeled J415.

In another setting, e.g. treatment, one could increase antibody binding by using a combination of non-competing monoclonal antibodies. For example, assuming the non-competing sites are each represented once on the prostate specific membrane antigen molecule, adding a combination of J591 plus J415 would bind twice as many monoclonal antibody molecules as either monoclonal antibody alone. Binding two non-competing antigenic binding sites also can result in greater antigen cross-linking and, perhaps, increased internalization. Furthermore, since the two detected sites are physically located on the same prostate specific membrane antigen molecule, the binding of two monoclonal antibody molecules to that single prostate specific membrane antigen molecule puts the two monoclonal antibody molecules in close proximity to each other, a setting which provides optimal drug-prodrug interaction. For example, monoclonal antibody J591 can be conjugated with an inactive pro-drug and J415 can be conjugated with a pro-drug activator. Since pro-drug and activator would be bound in close proximity only at the site of prostate specific membrane antigen-expressing cells (e.g., prostate cancer cells), prodrug activation to the active form would occur only at those sites.

#### Example 11

##### Microscopy

Confocal microscopy and immuno-electron microscopy demonstrated that E99, J591, J533, and J415 are bound to the cell membrane at clathrin-coated pits and then rapidly internalize into endosomes (cytoplasmic vesicles). FIGS. 1-4 are immuno-electron micrographs which follow the interaction of gold-labeled monoclonal antibody J591 with the cell surface as a function of time. In these figures, the location of the monoclonal antibody is indicated by the black dots.

Viable LNCaP cells were incubated with J591 for one hour at 4° C. The cells were washed and then held at 37° C. for 0, 5, 10, or 15 minutes, after which time they were fixed and processed for immuno-electron microscopy. FIG. 1 shows the cell prior to 37° C. incubation. J591 can be seen bound to the cell along the external aspect of the cell membrane. In this Figure, "M" denotes the cell's mitochondria, and "N" denotes its nucleus. FIG. 2 shows the cell after incubation at 37° C. for 5 minutes. The arrow indicates formation of a clathrin-coated pit. In FIG. 3, which shows the cell after a 10 minute 37° C. incubation, pinching off or endocytosis of the clathrin-coated pit can be seen, as indicated by the arrow. FIG. 4 shows that, after incubation at 37° C. for 15 minutes, monoclonal antibody J591 is contained in endocytic vesicles within the cell, as indicated by the arrows. As can be seen in FIG. 5, after incubation at 37° C. for 15 minutes, monoclonal antibody J591 is also contained within endosomes, as indicated by the arrows.

#### Example 12

##### Sequencing of the Variable Region of Monoclonal Antibody J591

Total RNA was prepared from 10<sup>7</sup> murine hybridoma J591 cells. A sample of the conditioned medium from these cells was tested for binding to the specific antigen for J591 on prostate cells. The conditioned medium was positive by both ELISA and Western Blot for binding to the antigen.

VH and VK cDNA were prepared using reverse transcriptase and mouse K constant region and mouse IgG constant region primers. The first strand cDNAs were amplified by PCR using a variety of mouse signal sequence primers (6 for VH and 7 for VK). The amplified DNAs were gel-purified and cloned into the vector pT7Blue.

The VH and VK clones obtained were screened for correct inserts by PCR, and the DNA sequence of selected clones was determined by the dideoxy chain termination method.

Excluding the primer region (as the sequence of this depended on the sequence of the primer that was used), all the VH clones obtained gave identical sequence. This sequence was obtained from clones produced with three different 5' primers. One clone had one base pair change within the signal sequence, and one clone contained an aberrant PCR product. Using the sequencing strategy shown in FIG. 6, the nucleotide sequence for the heavy chain was obtained. It is designated SEQ. ID. No. 1 and is presented in FIG. 7, along with the nucleotide sequence of the corresponding reverse, non-coding strand (designated SEQ. ID. No. 2). These sequences include part of the signal sequence and part of the constant region of the antibody. The corresponding deduced amino acid sequences of J591 VH, designated SEQ. ID. No. 3, SEQ. ID. No. 4, and SEQ. ID. No. 5, are also shown in FIG. 7. The coding strand of the J591 heavy chain's variable region (exclusive of signal sequence and constant region components) has the following nucleotide sequence (designated SEQ. ID. No. 6):

```
GAGGTCCAGCTGCAACAGTCTGGACCTGAACTGGTGAAGCCTGGGACTTC
AGTGAGGATATCCTGCAAGACTTCTGGATACACATTCAGTGAATATACCA
TACACTGGGTGAAGCAGAGCCATGGAAGAGCCTTGAGTGGATTGGAAGC
ATCAATCCTAACAATGGTGGTACCACCTACAATCAGAAGTTCGAGGACAA
GGCCACATTGACTGTAGACAAGTCTCCAGTACAGCCTACATGGAGCTCC
GCAGCCTAACATCTGAGGATTCTGCAGTCTATTATTGTGCAGCTGGTTGG
AACTTTGACTACTGGGGCCAGGCACCACTCTCACAGTCTCC TCA
TGAGGAGACTGTGAGAGTGGTGCCTTGGCCCCAGTAGTCAAAGTTCCAAC
CAGCTGCACAATAATAGACTGCAGAATCCTCAGATGTTAGGCTGCGGAGC
TCCATGTAGGCTGTACTGGAGGACTTGTCTACAGTCAATGTGGCCTTGTCT
CTCGAACTTCTGATTGTAGGTGGTACCACCATTTAGGATTGATGTTTC
CAATCCACTCAAGGCTCTTTCCATGGCTCTGCTTCACCCAGTGTATGGTA
TATTCAGTGAATGTGTATCCAGAAGTCTTGCAAGATATCCTCACTGAAGT
CCCAGGCTTCACCAAGTTCAGGTCCAGACTGTTGCAGCTGGACCTC
```



25

The protein sequence corresponding to the J591 heavy chain's variable region (exclusive of signal sequence and constant region components) has the following nucleotide sequence (designated SEQ. ID. No. 8):

EVQLQQSGPELVKPGTSSVRISCKTSGYTFTEYTIHWVKQSHGKSLIEWIGN  
INPNNGGTTYNQKFEDKATLTVDKSSSTAYMELRSLTSEDSSAVYYCAAGW  
NFDYWGQGTTLTVS S

The J591 VH is in Mouse Heavy Chains Subgroup IIA (Kabat et al., Sequences of Proteins of Immunological Interest, U.S. Department of Health and Human Services (1991) ("Kabat"), which is hereby incorporated by reference). The sequence of J591 VH is compared to the consensus sequence for this subgroup in FIG. 8.

In contrast to the VH, more than one VK sequence was obtained. Out of the 15 VK clones examined, four gave the sequence of an aberrant mouse IgK from the fusion partner (Carol et al., *Molecular Immunology*, 25:991-995 (1988), which is hereby incorporated by reference). These clones originated from two specific 5' primers. No further work was done with these clones. Of the remaining clones, ten gave identical nucleotide sequences, and one clone, VK17, gave an alternative VK sequence. The ten identical clones originated from three 5' primers (different from the two that gave the aberrant sequence), one of which also produced VK17. The sequencing strategy that was employed is shown in FIG. 9.

The nucleic acid sequence of J591 VK corresponding to the ten identical clones (designated SEQ. ID. No. 9) is presented in FIG. 10, along with the nucleic acid sequence of the corresponding reverse, non-coding strand (designated SEQ. ID. No. 10) and the deduced amino acid sequences, which are designated SEQ. ID. No. 11, SEQ. ID. No. 12, and SEQ. ID. No. 13. These sequences include part of the signal sequence and part of the constant region of the antibody. The coding strand of the J591 light (kappa) chain's variable region (exclusive of signal sequence and constant region components) corresponding to the ten identical clones has the following nucleotide sequence (designated SEQ. ID. No. 14):

AACATTGTAATGACCCAATCTCCAAATCCATGTCCATGTCCAGTAGGAGA  
GAGGGTCACCTTGACCTGCAAGGCCAGTGAGAATGTGGTTACTTATGTTT  
CCTGGTATCAACAGAAACCAGAGCAGTCTCCTAAACTGCTGATATACGGG  
GCATCCAACCGGTACACTGGGGTCCCCGATCGCTTCACAGGCAGTGGATC  
TGCAACAGATTCTACTCTGACCATCAGCAGTGTGACAGGCTGAAGACCTTG  
CAGATTATCACTGTGGACAGGGTTACAGCTATCCGTACACGTTTCGGAGGG  
GGGACCAAGCTGGAAATAAAA

The reverse, non-coding strand of the J591 light (kappa) chain's variable region (exclusive of signal sequence and constant region components) corresponding to the ten identical clones has the following nucleotide sequence (designated SEQ. ID. No. 15):

TTTTATTTCAGCTTGGTCCCCCTCCGAACGTGTACGGATAGCTGTAAC  
CCTGTCCACAGTGATAATCTGCAAGGTCTTCAGCCTGCACACTGCTGATG  
GTCAGAGTGAAATCTGTTGCAGATCCACTGCCTGTGAAGCGATCGGGGAC

26

-continued

CCCAGTGTAACGGTTGGATGCCCCGTATATCAGCAGTTTAGGAGACTGCT  
CTGGTTTCTGTTGATACCAGGAACATAAGTAACACATTCTCACTGGGCC  
5 TTGCAGGTCAAGGTGACCCCTCTCTCTACTGACATGGACATGGATTGGG  
AGATTGGGTCATTACAATGTT

The protein sequence corresponding to the J591 light (kappa) chain's variable region (exclusive of signal sequence and constant region components) corresponding to the ten identical clones has the following nucleotide sequence (designated SEQ. ID. No. 16):

10 NIVMTQSPKMSMSVGERVTLTKASENVVTVSWYQQKPEQSPKLLIYG  
ASNRYTG VPDRTFTSGSATDFTLTISVQAEDLADYHCGQGYSPYPTFG  
GGTKLEIK

The coding strand of the J591 light (kappa) chain's variable region (exclusive of signal sequence and constant region components) corresponding to clone VK17 has the following nucleotide sequence (designated SEQ. ID. No. 17):

25 GACATTGTGATGACCCAGTCTCACAATTCATGTCCACATCAGTAGGAGA  
CAGGGTCAGCATCATCTGTAAGGCCAGTCAAGATGTGGGTACTGCTGTAG  
ACTGGTATCAACAGAAACCAGGACAATCTCCTAACTACTGATTATTGG  
30 GCATCCACTCGGCACACTGGAGTCCCTGATCGCTTCACAGGCAGTGGATC  
TGGGACAGACTTCACTCTCACCATTACTAATGTTTCAGTCTGAAGACTTGG  
CAGATTATTTCTGTGCAATATAACAGCTATCCTCTCAGCTTCGGTGCT  
35 GGGACCATGCTGGACCTGAAA

The reverse, non-coding strand of the J591 light (kappa) chain's variable region (exclusive of signal sequence and constant region components) corresponding to clone VK17 has the following nucleotide sequence (designated SEQ. ID. No. 18):

TTTCAGGTCCAGCATGGTCCCAGCACCGAACGTGAGAGGATAGCTGTTAT  
45 ATTGCTGACAGAAATAATCTGCCAAGTCTTCAGACTGAACATTAGTAATG  
GTGAGAGTGAAGTCTGTCCAGATCCACTGCCTGTGAAGCGATCAGGGAC  
TCCAGTGTGCCAGTGGATGCCAATAAATCAGTAGTTTAGGAGATTGTC  
50 CTGGTTTCTGTTGATACCAGTCTACAGCAGTACCCACATCTTGACTGGCC  
TTACAGATGATGCTGACCCGTCTCTCTACTGATGGACATGAATTTGTG  
AGACTGGGTCATCACAATGTC

The protein sequence corresponding to the J591 light (kappa) chain's variable region (exclusive of signal sequence and constant region components) corresponding to clone VK17 has the following nucleotide sequence (designated SEQ. ID. No. 19):

60 DIVMTQSHKFMSTSVGDRVSIICKASQDVGTAVDWYQQKPGQSPKLLIYW  
ASTRHTG VPDRTFTSGSGTDFTLTIINVSQEDLADYFCQYNSYPLTFG  
AGTMLDLK

65 J591 VK is in the Mouse Kappa Chains Subgroup V (Kabat, which is hereby incorporated by reference). The

sequence of J591 VK corresponding to the ten identical clones is compared to the consensus sequence for the subgroup in FIG. 11.

Preferred J591's are those having heavy chain variable region DNA coding strand sequences corresponding to SEQ. ID. No. 6 and non-coding strand (reverse) sequences corresponding to SEQ. ID. No. 7. The heavy chain variable region of J591 preferably has an amino acid sequence corresponding to SEQ. ID. No. 8. The light chain variable region of J591 preferably has a DNA coding strand sequence corresponding to SEQ. ID. No. 17, a DNA non-coding strand (reverse) sequence corresponding to SEQ. ID. No. 18, and a amino acid sequence corresponding to SEQ. ID. No. 19.

#### Example 13

##### Immunohistochemical Staining of Normal and Cancer Tissues

Cancer tissues from 23 carcinomas were pre-cooled in liquid nitrogen, snap-frozen in OCT compound (Miles,

Elkhart, Ind.) on dry ice, and stored at  $-80^{\circ}\text{C}$ . Cryostat tissue sections ( $5\text{ }\mu\text{m}$ ) were fixed in cold acetone ( $4^{\circ}\text{C}$ .) for 10 minutes. mAbs ( $5\text{ }\mu\text{g/ml}$  or hybridoma supernatants) were incubated for 1 hour at room temperature. Antibody binding was detected using rabbit anti-mouse Ig-peroxidase (Dako, Carpinteria, Calif.) as a secondary antibody and DAB (Sigma, St. Louis, Mo.) as chromogen. Isotype-matched irrelevant antibody was used as negative control.

mAbs J591, J533, J415, and E99 reacted strongly with vascular endothelia in all 23 carcinomas studied, including 9/9 renal, 5/5 urothelial, 6/6 colon, 1/1 lung, and 1/1 breast carcinomas, and 1/1 metastatic adenocarcinoma to the liver FIGS. 12A-12F, respectively, show the immunohistochemical reactivity of mAb J591 to neovasculature of renal, urothelial, colon, lung, and breast carcinomas, and metastatic adenocarcinoma to the liver.

Although the invention has been described in detail for the purpose of illustration, it is understood that such detail is solely for that purpose and variations can be made by those skilled in the art without departing from the spirit and scope of the invention which is defined by the following claims.

---

#### SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 21

<210> SEQ ID NO 1

<211> LENGTH: 391

<212> TYPE: DNA

<213> ORGANISM: Mus sp.

<400> SEQUENCE: 1

```
tctcctgtca ggaactgcag gtgtcctctc tgaggccag ctgcaacagt ctggacctga      60
actggtgaag cctgggactt cagtggagat atcctgcaag acttctggat acacattcac      120
tgaatatacc atacactggg tgaagcagag ccatggaaag agccttgagt ggattggaaa      180
catcaatcct aacaatgggt gtaccaccta caatcagaag ttcgaggaca aggccacatt      240
gactgtagac aagtcctcca gtacagccta catggagctc cgcagcctaa catctgagga      300
ttctgcagtc tattattgtg cagctgggtg gaactttgac tactggggcc aaggcaccac      360
tctcacagtc tctcagcca aaacgacacc c                                     391
```

<210> SEQ ID NO 2

<211> LENGTH: 391

<212> TYPE: DNA

<213> ORGANISM: Mus sp.

<400> SEQUENCE: 2

```
gggtgtcggt ttggctgagg agactgtgag agtgggtgcct tggccccagt agtcaaagtt      60
ccaaccagct gcacaataat agactgcaga atcctcagat gtaggctgc ggagctccat      120
gtaggctgta ctggaggact tgtctacagt caatgtggcc ttgtcctcga acttctgatt      180
gtaggtggta ccaccattgt taggattgat gttccaatc cactcaaggc tctttccatg      240
gctctgcttc acccagtgta tggatatctc agtgaatgtg tatccagaag tcttgaggga      300
tatactcact gaagtccag gcttcaccag ttcagggtcca gactgttgca gctggacctc      360
agagaggaca cctgcagttc ctacgaggag a                                     391
```

<210> SEQ ID NO 3

<211> LENGTH: 123

<212> TYPE: PRT

<213> ORGANISM: Mus sp.

-continued

&lt;400&gt; SEQUENCE: 3

```

Ser Pro Val Arg Asn Cys Arg Cys Pro Leu Gly Pro Ala Ala Thr Val
1           5           10           15

Trp Thr Thr Gly Glu Ala Trp Asp Phe Ser Glu Asp Ile Leu Gln Asp
          20           25           30

Phe Trp Ile His Ile His Ile Tyr His Thr Leu Gly Glu Ala Glu Pro
          35           40           45

Trp Lys Glu Pro Val Asp Trp Lys His Gln Ser Gln Trp Trp Tyr His
          50           55           60

Leu Gln Ser Glu Val Arg Gly Gln Gly His Ile Asp Cys Arg Gln Val
          65           70           75           80

Leu Gln Tyr Ser Leu His Gly Ala Pro Gln Pro Asn Ile Gly Phe Cys
          85           90           95

Ser Leu Leu Leu Cys Ser Trp Leu Glu Leu Leu Leu Gly Pro Arg His
          100          105          110

His Ser His Ser Leu Leu Ser Gln Asn Asp Thr
          115          120

```

<210> SEQ ID NO 4  
 <211> LENGTH: 130  
 <212> TYPE: PRT  
 <213> ORGANISM: Mus sp.

&lt;400&gt; SEQUENCE: 4

```

Leu Leu Ser Gly Thr Ala Gly Val Leu Ser Glu Val Gln Leu Gln Gln
1           5           10           15

Ser Gly Pro Glu Leu Val Lys Pro Gly Thr Ser Val Arg Ile Ser Cys
          20           25           30

Lys Thr Ser Gly Tyr Thr Phe Thr Glu Tyr Thr Ile His Trp Val Lys
          35           40           45

Gln Ser His Gly Lys Ser Leu Glu Trp Ile Gly Asn Ile Asn Pro Asn
          50           55           60

Asn Gly Gly Thr Thr Tyr Asn Gln Lys Phe Glu Asp Lys Ala Thr Leu
          65           70           75           80

Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr Met Glu Leu Arg Ser Leu
          85           90           95

Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys Ala Ala Gly Trp Asn Phe
          100          105          110

Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser Ala Lys Thr
          115          120          125

Thr Pro
          130

```

<210> SEQ ID NO 5  
 <211> LENGTH: 125  
 <212> TYPE: PRT  
 <213> ORGANISM: Mus sp.

&lt;400&gt; SEQUENCE: 5

```

Leu Ser Cys Gln Glu Leu Gln Val Ser Ser Leu Arg Ser Ser Cys Asn
1           5           10           15

Ser Leu Asp Leu Asn Trp Ser Leu Gly Leu Gln Gly Tyr Pro Ala Arg
          20           25           30

Leu Leu Asp Thr His Ser Leu Asn Ile Pro Tyr Thr Gly Ser Arg Ala
          35           40           45

```

-continued

---

Met	Glu	Arg	Ala	Leu	Ser	Gly	Leu	Glu	Thr	Ser	Ile	Leu	Thr	Met	Val
50						55					60				

Val	Pro	Pro	Thr	Ile	Arg	Ser	Ser	Arg	Thr	Arg	Pro	His	Leu	Thr	Ser
65					70				75					80	

Pro	Pro	Val	Gln	Pro	Thr	Trp	Ser	Ser	Ala	Ala	His	Leu	Arg	Ile	Leu
			85						90					95	

Gln	Ser	Ile	Ile	Val	Gln	Leu	Val	Gly	Thr	Leu	Thr	Thr	Gly	Ala	Lys
			100					105					110		

Ala	Pro	Leu	Ser	Gln	Pro	Ser	Gln	Pro	Lys	Arg	His	Pro
	115						120				125	

&lt;210&gt; SEQ ID NO 6

&lt;211&gt; LENGTH: 345

&lt;212&gt; TYPE: DNA

&lt;213&gt; ORGANISM: Mus sp.

&lt;400&gt; SEQUENCE: 6

gaggtccagc	tgcaacagtc	tggacctgaa	ctggtgaagc	ctgggacttc	agtgaggata	60
tcctgcaaga	cttctggata	cacattcact	gaatatacca	tacactgggt	gaagcagagc	120
catggaaaga	gccttgagtg	gattggaaac	atcaatccta	acaatggtgg	taccacctac	180
aatcagaagt	tcgaggacaa	ggccacattg	actgtagaca	agtcctccag	tacagcctac	240
atggagctcc	gcagcctaac	atctgaggat	tctgcagtct	attattgtgc	agctggttgg	300
aactttgact	actggggcca	aggcaccact	ctcacagtct	cctca		345

&lt;210&gt; SEQ ID NO 7

&lt;211&gt; LENGTH: 345

&lt;212&gt; TYPE: DNA

&lt;213&gt; ORGANISM: Mus sp.

&lt;400&gt; SEQUENCE: 7

tgaggagact	gtgagagtgg	tgccttggcc	ccagtagtca	aagttccaac	cagctgcaca	60
ataatagact	gcagaatcct	cagatgttag	gctgcggagc	tccatgtagg	ctgtactgga	120
ggacttgtct	acagtcaatg	tggccttgtc	ctcgaacttc	tgattgtagg	tggtaccacc	180
attgttagga	ttgatgttcc	caatccactc	aaggctcttt	ccatggctct	gcttcacca	240
gtgtatggta	tattcagtga	atgtgtatcc	agaagtcttg	caggatatcc	tactgaagt	300
cccaggcttc	accagttcag	gtccagactg	ttgcagctgg	acctc		345

&lt;210&gt; SEQ ID NO 8

&lt;211&gt; LENGTH: 115

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Mus sp.

&lt;400&gt; SEQUENCE: 8

Glu	Val	Gln	Leu	Gln	Gln	Ser	Gly	Pro	Glu	Leu	Val	Lys	Pro	Gly	Thr
1				5					10					15	

Ser	Val	Arg	Ile	Ser	Cys	Lys	Thr	Ser	Gly	Tyr	Thr	Phe	Thr	Glu	Tyr
			20					25					30		

Thr	Ile	His	Trp	Val	Lys	Gln	Ser	His	Gly	Lys	Ser	Leu	Glu	Trp	Ile
	35						40					45			

Gly	Asn	Ile	Asn	Pro	Asn	Asn	Gly	Gly	Thr	Thr	Tyr	Asn	Gln	Lys	Phe
	50					55					60				

Glu	Asp	Lys	Ala	Thr	Leu	Thr	Val	Asp	Lys	Ser	Ser	Ser	Thr	Ala	Tyr
65					70					75				80	

-continued

---

Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys  
85 90 95

Ala Ala Gly Trp Asn Phe Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr  
100 105 110

Val Ser Ser  
115

<210> SEQ ID NO 9  
<211> LENGTH: 363  
<212> TYPE: DNA  
<213> ORGANISM: Mus sp.

<400> SEQUENCE: 9

```

ttatatggag ctgatgggaa cattgtaatg acccaatctc ccaaattccat gtccatgtca    60
gtaggagaga gggtcacctt gacctgcaag gccagtgaga atgtgggttac ttatgtttcc    120
tggtatcaac agaaaccaga gcagtctcct aaactgctga tatacggggc atccaaccgg    180
tacactgggg tccccgatcg cttcacaggg agtggatctg caacagattt cactctgacc    240
atcagcagtg tgcaggctga agaccttgca gattatcact gtggacaggg ttacagctat    300
ccgtacacgt tcggaggggg gaccaagctg gaaataaaac gggctgatgc tgcaccaact    360
gta                                                                    363

```

<210> SEQ ID NO 10  
<211> LENGTH: 363  
<212> TYPE: DNA  
<213> ORGANISM: Mus sp.

<400> SEQUENCE: 10

```

tacagttggt gcagcatcag cccgttttat ttccagcttg gtccccctc cgaacgtgta    60
cggatagctg taacctgtgc cacagtgata atctgcaagg tcttcagcct gcacactgct    120
gatggtcaga gtgaaatctg ttgcagatcc actgcctgtg aagcgatcgg ggaccccagt    180
gtaccggttg gatgccccgt atatcagcag ttaggagac tgctctgggt tctgttgata    240
ccaggaaaca taagtaacca cattctcact ggcttgacg gtcaagggtga cctctctccc    300
tactgacatg gacatggatt tgggagattg ggctattaca atgttcccat cagctccata    360
taa                                                                    363

```

<210> SEQ ID NO 11  
<211> LENGTH: 121  
<212> TYPE: PRT  
<213> ORGANISM: Mus sp.

<400> SEQUENCE: 11

Leu Tyr Gly Ala Asp Gly Asn Ile Val Met Thr Gln Ser Pro Lys Ser  
1 5 10 15

Met Ser Met Ser Val Gly Glu Arg Val Thr Leu Thr Cys Lys Ala Ser  
20 25 30

Glu Asn Val Val Thr Tyr Val Ser Trp Tyr Gln Gln Lys Pro Glu Gln  
35 40 45

Ser Pro Lys Leu Leu Ile Tyr Gly Ala Ser Asn Arg Tyr Thr Gly Val  
50 55 60

Pro Asp Arg Phe Thr Gly Ser Gly Ser Ala Thr Asp Phe Thr Leu Thr  
65 70 75 80

Ile Ser Ser Val Gln Ala Glu Asp Leu Ala Asp Tyr His Cys Gly Gln  
85 90 95

-continued

---

Gly Tyr Ser Tyr Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile  
                   100                  105                  110

Lys Arg Ala Asp Ala Ala Pro Thr Val  
           115                  120

<210> SEQ ID NO 12  
 <211> LENGTH: 114  
 <212> TYPE: PRT  
 <213> ORGANISM: Mus sp.

<400> SEQUENCE: 12

Tyr Met Glu Leu Met Gly Thr Leu Pro Asn Leu Pro Asn Pro Cys Pro  
 1                  5                  10                  15

Cys Gln Glu Arg Gly Ser Pro Pro Ala Arg Pro Val Arg Met Trp Leu  
                   20                  25                  30

Leu Met Phe Pro Gly Ile Asn Arg Asn Gln Ser Ser Leu Leu Asn Cys  
           35                  40                  45

Tyr Thr Gly His Pro Thr Gly Thr Leu Gly Ser Pro Ile Ala Ser Gln  
           50                  55                  60

Ala Val Asp Leu Gln Gln Ile Ser Leu Pro Ser Ala Val Cys Arg Leu  
 65                  70                  75                  80

Lys Thr Leu Gln Ile Ile Thr Val Asp Arg Val Thr Ala Ile Arg Thr  
                   85                  90                  95

Arg Ser Glu Gly Gly Pro Ser Trp Lys Asn Gly Leu Met Leu His Gln  
                   100                  105                  110

Leu Tyr

<210> SEQ ID NO 13  
 <211> LENGTH: 116  
 <212> TYPE: PRT  
 <213> ORGANISM: Mus sp.

<400> SEQUENCE: 13

Ile Ile Trp Ser Trp Glu His Cys Asn Asp Pro Ile Ser Gln Ile His  
 1                  5                  10                  15

Val His Val Ser Arg Arg Glu Gly His Leu Asp Leu Gln Gly Gln Glu  
                   20                  25                  30

Cys Gly Tyr Leu Cys Phe Leu Val Ser Thr Glu Thr Arg Ala Val Ser  
           35                  40                  45

Thr Ala Asp Ile Arg Gly Ile Gln Pro Val His Trp Gly Pro Arg Ser  
           50                  55                  60

Leu His Arg Gln Trp Ile Cys Asn Arg Phe His Ser Asp His Gln Gln  
 65                  70                  75                  80

Cys Ala Gly Arg Pro Cys Arg Leu Ser Leu Trp Thr Gly Leu Gln Leu  
                   85                  90                  95

Ser Val His Val Arg Arg Gly Asp Gln Ala Gly Asn Lys Thr Gly Cys  
                   100                  105                  110

Cys Thr Asn Cys  
           115

<210> SEQ ID NO 14  
 <211> LENGTH: 321  
 <212> TYPE: DNA  
 <213> ORGANISM: Mus sp.

-continued

&lt;400&gt; SEQUENCE: 14

```

aacattgtaa tgacccaatc tcccaaatcc atgtccatgt cagtaggaga gagggtcacc      60
ttgacctgca aggccagtga gaatgtgggtt acttatgttt cctggatatca acagaaacca    120
gagcagtcctc ctaaaactgct gatatacggg gcatccaacc ggtacactgg ggtccccgat    180
cgcttcacag gcagtggatc tgcaacagat ttcactctga ccatcagcag tgtgcaggct     240
gaagaccttg cagattatca ctgtggacag ggttacagct atccgtacac gttcggaggg     300
gggaccaagc tggaaataaa a                                           321

```

&lt;210&gt; SEQ ID NO 15

&lt;211&gt; LENGTH: 321

&lt;212&gt; TYPE: DNA

&lt;213&gt; ORGANISM: Mus sp.

&lt;400&gt; SEQUENCE: 15

```

ttttatttcc agcttgggtcc cccctccgaa cgtgtacgga tagctgtaac cctgtccaca      60
gtgataatct gcaagggtctt cagcctgcac actgctgatg gtcagagtga aatctgttgc     120
agatccactg cctgtgaagc gatcggggac cccagtgtac cggttggatg ccccgatatat    180
cagcagttta ggagactgct ctggtttctg ttgataccag gaaacataag taaccacatt     240
ctcactggcc ttgcagggtca aggtgaccct ctctcctact gacatggaca tggatttggg     300
agattgggtc attacaatgt t                                           321

```

&lt;210&gt; SEQ ID NO 16

&lt;211&gt; LENGTH: 107

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Mus sp.

&lt;400&gt; SEQUENCE: 16

```

Asn Ile Val Met Thr Gln Ser Pro Lys Ser Met Ser Met Ser Val Gly
1       5       10      15
Glu Arg Val Thr Leu Thr Cys Lys Ala Ser Glu Asn Val Val Thr Tyr
20      25      30
Val Ser Trp Tyr Gln Gln Lys Pro Glu Gln Ser Pro Lys Leu Leu Ile
35      40      45
Tyr Gly Ala Ser Asn Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly
50      55      60
Ser Gly Ser Ala Thr Asp Phe Thr Leu Thr Ile Ser Ser Val Gln Ala
65      70      75      80
Glu Asp Leu Ala Asp Tyr His Cys Gly Gln Gly Tyr Ser Tyr Pro Tyr
85      90      95
Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
100     105

```

&lt;210&gt; SEQ ID NO 17

&lt;211&gt; LENGTH: 321

&lt;212&gt; TYPE: DNA

&lt;213&gt; ORGANISM: Mus sp.

&lt;400&gt; SEQUENCE: 17

```

gacattgtga tgacccagtc tcacaaatcc atgtccacat cagtaggaga cagggtcagc      60
atcatctgta aggccagtca agatgtgggt actgctgtag actggatatca acagaaacca    120
ggacaatctc ctaaaactact gatttattgg gcatccactc ggcacactgg agtccctgat    180
cgcttcacag gcagtggatc tgggacagac ttcactctca ccattactaa tgttcagtct     240

```

-continued

---

```
gaagacttgg cagattatct ctgtcagcaa tataacagct atcctctcac gttcgggtgct 300
gggaccatgc tggacctgaa a 321
```

```
<210> SEQ ID NO 18
<211> LENGTH: 321
<212> TYPE: DNA
<213> ORGANISM: Mus sp.
```

```
<400> SEQUENCE: 18
```

```
tttcaggtcc agcatggtcc cagcaccgaa cgtgagagga tagctgttat attgctgaca 60
gaaataatct gccaaagtctt cagactgaac attagtaatg gtgagagtga agtctgtccc 120
agatccactg cctgtgaagc gatcaggac tccagtgtgc cgagtggatg cccaataaat 180
cagtagttta ggagattgtc ctggtttctg ttgataccag tctacagcag taccacatc 240
ttgactggcc ttacagatga tgctgacct gtctcctact gatgtggaca tgaatttgtg 300
agactgggtc atcacaatgt c 321
```

```
<210> SEQ ID NO 19
<211> LENGTH: 107
<212> TYPE: PRT
<213> ORGANISM: Mus sp.
```

```
<400> SEQUENCE: 19
```

```
Asp Ile Val Met Thr Gln Ser His Lys Phe Met Ser Thr Ser Val Gly
1 5 10 15
Asp Arg Val Ser Ile Ile Cys Lys Ala Ser Gln Asp Val Gly Thr Ala
20 25 30
Val Asp Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile
35 40 45
Tyr Trp Ala Ser Thr Arg His Thr Gly Val Pro Asp Arg Phe Thr Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Thr Asn Val Gln Ser
65 70 75 80
Glu Asp Leu Ala Asp Tyr Phe Cys Gln Gln Tyr Asn Ser Tyr Pro Leu
85 90 95
Thr Phe Gly Ala Gly Thr Met Leu Asp Leu Lys
100 105
```

```
<210> SEQ ID NO 20
<211> LENGTH: 125
<212> TYPE: PRT
<213> ORGANISM: Mus sp.
```

```
<400> SEQUENCE: 20
```

```
Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala
1 5 10 15
Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
20 25 30
Tyr Met Asn Asn Trp Val Lys Gln Ser Pro Gly Lys Ser Leu Glu Trp
35 40 45
Ile Gly Asp Ile Asn Pro Gly Asn Gly Gly Thr Ser Tyr Asn Gln Lys
50 55 60
Phe Lys Gly Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala
65 70 75 80
Tyr Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr
85 90 95
```



-continued

---

Cys Ala Arg Gly Tyr Tyr Ser Ser Ser Tyr Met Ala Tyr Tyr Ala Phe  
                   100                  105                  110

Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser  
           115                  120                  125

<210> SEQ ID NO 21  
 <211> LENGTH: 109  
 <212> TYPE: PRT  
 <213> ORGANISM: Mus sp.

<400> SEQUENCE: 21

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Leu Gly  
 1                  5                  10                  15

Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Asp Ile Ser Asn  
           20                  25                  30

Tyr Leu Asn Trp Tyr Gln Gln Lys Pro Gly Gly Ser Pro Lys Leu Leu  
           35                  40                  45

Ile Tyr Tyr Ala Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser  
           50                  55                  60

Gly Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu  
  65                  70                  75                  80

Gln Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly Asn Thr Leu Pro  
           85                  90                  95

Pro Arg Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys  
           100                  105

---

What is claimed:

1. A method of detecting cancerous tissue in a biological tissue sample comprising:

providing an antibody or antigen binding portion thereof which, when contacted with an extracellular domain of prostate specific membrane antigen, binds to the extracellular domain of prostate specific membrane antigen, wherein the antibody or antigen binding portion thereof is bound to a label effective to permit detection of vascular endothelial cells proximate to or within the cancerous tissue upon binding of the antibody or antigen binding portion thereof to the vascular endothelial cells proximate to or within the cancerous tissue;

contacting the biological tissue sample with the antibody or antigen binding portion thereof having a label under conditions effective to permit binding of the antibody or antigen binding portion thereof to the vascular endothelial cells proximate to or within the cancerous tissue in the biological tissue sample;

detecting a presence of any cancerous tissue in the biological tissue sample by detecting the label; and wherein the antibody is a monoclonal antibody produced by a hybridoma cell line having an ATCC Accession Number selected from the group consisting of HB-12101, HB-12109, HB-12127, and HB-12126.

2. A method according to claim 1, wherein the cancerous tissue is renal cancerous tissue, urothelial cancerous tissue, colon cancerous tissue, rectal cancerous tissue, lung cancerous tissue, breast cancerous tissue, or cancerous tissue of metastatic adenocarcinoma to the liver.

3. A method according to claim 1, wherein the antibody or antigen binding portion thereof, when contacted with the extracellular domain of prostate specific membrane antigen, is internalized with the prostate specific membrane antigen.

4. A method according to claim 1, wherein said contacting is carried out in a living mammal and comprises: administering the antibody or antigen binding portion thereof to the living mammal under conditions effective to permit in vivo binding of the antibody or antigen binding portion thereof to the vascular endothelial cells proximate to or within the cancerous tissue in the living mammal.

5. A method according to claim 4, wherein the label is a short-range radiation emitter.

6. A method according to claim 1, wherein the antigen binding portion thereof is selected from the group consisting of an F(ab')<sub>2</sub> fragment, an F(ab')<sub>2</sub> fragment, and an Fv fragment.

7. A method according to claim 1, wherein the label is selected from the group consisting of a fluorescent label, a radioactive label, a nuclear magnetic resonance active label, a luminescent label, and a chromophore label.

8. A method according to claim 1, wherein the antibody or antigen binding portion thereof is in a composition further comprising a physiologically acceptable carrier, excipient, or stabilizer.

9. A method according to claim 1, wherein the antibody or antigen binding portion thereof is in a composition further comprising a pharmaceutically acceptable carrier, excipient, or stabilizer.

10. A method according to claim 1, wherein said contacting is carried out in a tissue biopsy sample.

11. A method of detecting cancerous tissue in a biological tissue sample comprising:

providing an antibody or antigen binding portion thereof which, when contacted with an extracellular domain of prostate specific membrane antigen, binds to the extracellular domain of prostate specific membrane antigen, wherein the antibody or antigen binding portion thereof is bound to a label effective to permit detection of vascular endothelial cells proximate to or within the can-

cerous tissue upon binding of the antibody or antigen binding portion thereof to the vascular endothelial cells proximate to or within the cancerous tissue;  
 contacting the biological tissue sample with the antibody or antigen binding portion thereof having a label under conditions effective to permit binding of the antibody or antigen binding portion thereof to the vascular endothelial cells proximate to or within the cancerous tissue in the biological tissue sample;  
 detecting a presence of any cancerous tissue in the biological tissue sample by detecting the label; and  
 wherein the antibody is a monoclonal antibody selected from the group consisting of E99, J415, J533, and J591.

**12.** A method of detecting cancerous tissue in a biological tissue sample comprising:

providing an antibody or antigen binding portion thereof which, when contacted with an extracellular domain of prostate specific membrane antigen, binds to the extracellular domain of prostate specific membrane antigen, wherein the antibody or antigen binding portion thereof is bound to a label effective to permit detection of vascular endothelial cells proximate to or within the cancerous tissue upon binding of the antibody or antigen binding portion thereof to the vascular endothelial cells proximate to or within the cancerous tissue;

contacting the biological tissue sample with the antibody or antigen binding portion thereof having a label under conditions effective to permit binding of the antibody or antigen binding portion thereof to the vascular endothelial cells proximate to or within the cancerous tissue in the biological tissue sample;

detecting a presence of any cancerous tissue in the biological tissue sample by detecting the label; and  
 wherein the antibody or antigen binding portion thereof binds to an epitope of prostate specific membrane antigen which is also recognized by a monoclonal antibody selected from the group consisting of E99, J415, J533, and J591.

**13.** A method according to claim **12**, wherein the antibody or antigen binding portion thereof binds an epitope of prostate specific membrane antigen which is also recognized by monoclonal antibody J591.

**14.** A method of detecting cancerous tissue in a biological tissue sample comprising:

providing an antibody or antigen binding portion thereof which, when contacted with an extracellular domain of prostate specific membrane antigen, binds to the extracellular domain of prostate specific membrane antigen, wherein the antibody or antigen binding portion thereof is bound to a label effective to permit detection of vascular endothelial cells proximate to or within the cancerous tissue upon binding of the antibody or antigen binding portion thereof to the vascular endothelial cells proximate to or within the cancerous tissue;

contacting the biological tissue sample with the antibody or antigen binding portion thereof having a label under conditions effective to permit binding of the antibody or antigen binding portion thereof to the vascular endothelial cells proximate to or within the cancerous tissue in the biological tissue sample;

detecting a presence of any cancerous tissue in the biological tissue sample by detecting the label; and  
 wherein the antibody or antigen binding portion thereof comprises an antigen binding portion of an amino acid sequence selected from the group consisting of SEQ ID NO:8 (variable heavy chain), SEQ ID NO:19 (variable light chain), an amino acid sequence of the variable

heavy chain produced by the hybridoma having ATCC deposit no. HB-12126, and an amino acid sequence of the variable light chain by the hybridoma having ATCC deposit no. HB-12126.

**15.** A method according to claim **14**, wherein the antibody or antigen binding portion thereof comprises an antigen binding portion of an amino acid sequence of SEQ ID NO:8 (variable heavy chain) or an amino acid sequence of the variable heavy chain produced by the hybridoma having ATCC deposit no. HB-12126 and an antigen binding portion of an amino acid sequence of SEQ ID NO:19 (variable light chain) or an amino acid sequence of the variable light chain produced by the hybridoma having ATCC deposit no. HB-12126.

**16.** A method according to claim **14**, wherein the antibody or antigen binding portion thereof comprises an antigen binding portion of an amino acid sequence selected from the group consisting of an amino acid sequence of the variable heavy chain produced by the hybridoma having ATCC deposit no. HB-12126, and an amino acid sequence of the variable light chain produced by the hybridoma having ATCC deposit no. HB-12126.

**17.** A method according to claim **14**, wherein the antibody or antigen binding portion thereof comprises an antigen binding portion of an amino acid sequence of the variable heavy chain produced by the hybridoma having ATCC deposit no. HB-12126 and an antigen binding portion of an amino acid sequence of the variable light chain produced by the hybridoma having ATCC deposit no. HB-12126.

**18.** A method of detecting cancerous tissue in a biological tissue sample comprising:

providing an antibody or antigen binding portion thereof which, when contacted with an extracellular domain of prostate specific membrane antigen, binds to the extracellular domain of prostate specific membrane antigen, wherein the antibody or antigen binding portion thereof is bound to a label effective to permit detection of vascular endothelial cells proximate to or within the cancerous tissue upon binding of the antibody or antigen binding portion thereof to the vascular endothelial cells proximate to or within the cancerous tissue;

contacting the biological tissue sample with the antibody or antigen binding portion thereof having a label under conditions effective to permit binding of the antibody or antigen binding portion thereof to the vascular endothelial cells proximate to or within the cancerous tissue in the biological tissue sample;

detecting a presence of any cancerous tissue in the biological tissue sample by detecting the label; and

wherein the antibody or antigen binding portion thereof comprises an antigen binding portion of an amino acid sequence encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NO:6 (variable heavy chain), SEQ ID NO:17 (variable light chain), a nucleic acid sequence which encodes the variable heavy chain produced by the hybridoma having ATCC deposit no. HB-12126, and a nucleic acid sequence which encodes the variable light chain produced by the hybridoma having ATCC deposit no. HB-12126.

**19.** A method according to claim **18**, wherein the antibody or antigen binding portion thereof comprises an antigen binding portion encoded by a nucleic acid sequence of SEQ ID NO:6 (variable heavy chain) or a nucleic acid sequence which encodes the variable heavy chain of the hybridoma having ATCC deposit no. HB-12126 and an antigen binding portion encoded by a nucleic acid sequence of SEQ ID NO:17 (vari-

able light chain) or a nucleic acid sequence which encodes the variable light chain produced by the hybridoma having ATCC deposit no. HB-12126.

20. A method according to claim 18, wherein the antibody or antigen binding portion thereof comprises an antigen binding portion of an amino acid sequence encoded by a nucleic acid sequence selected from the group consisting of a nucleic acid sequence which encodes the variable heavy chain produced by the hybridoma having ATCC deposit no. HB-12126, and a nucleic acid sequence which encodes the variable light chain produced by the hybridoma having ATCC deposit no. HB-12126.

21. A method according to claim 18, wherein the antibody or antigen binding portion thereof comprises an antigen binding portion of an amino acid sequence encoded by a nucleic acid which encodes the variable heavy chain produced by the hybridoma having ATCC deposit no. HB-12126 and an antigen binding portion of an amino acid sequence encoded by a nucleic acid which encodes the variable light chain produced by the hybridoma having ATCC deposit no. HB-12126.

22. A method according to claim 12, wherein the antibody or antigen binding portion thereof binds to an epitope of prostate specific membrane antigen which is also recognized by the monoclonal antibody J415.

23. A method of detecting cancerous tissue in a biological tissue sample comprising:

providing an antibody or antigen binding portion thereof which, when contacted with an extracellular domain of prostate specific membrane antigen, binds to the extracellular domain of prostate specific membrane antigen, wherein the antibody or antigen binding portion thereof is bound to a label effective to permit detection of vascular endothelial cells proximate to or within the cancerous tissue upon binding of the antibody or antigen binding portion thereof to the vascular endothelial cells proximate to or within the cancerous tissue;

contacting the biological tissue sample with the antibody or antigen binding portion thereof having a label under conditions effective to permit binding of the antibody or antigen binding portion thereof to the vascular endothelial cells proximate to or within the cancerous tissue in the biological tissue sample;

detecting a presence of any cancerous tissue in the biological tissue sample by detecting the label; and

wherein the antibody or antigen binding portion thereof comprises an antigen binding portion of an amino acid sequence selected from the group consisting of an amino acid sequence of the variable heavy chain produced by the hybridoma having ATCC deposit no. HB-12109, and an amino acid sequence of the variable light chain produced by the hybridoma having ATCC deposit no. HB-12109.

24. A method according to claim 23, wherein the antibody or antigen binding portion thereof comprises an antigen binding portion of an amino acid sequence of the variable heavy chain produced by the hybridoma having ATCC deposit no. HB-12109 and an antigen binding portion of an amino acid

sequence of the variable light chain produced by the hybridoma having ATCC deposit no. HB-12109.

25. A method of detecting cancerous tissue in a biological tissue sample comprising:

providing an antibody or antigen binding portion thereof which, when contacted with an extracellular domain of prostate specific membrane antigen, binds to the extracellular domain of prostate specific membrane antigen, wherein the antibody or antigen binding portion thereof is bound to a label effective to permit detection of vascular endothelial cells proximate to or within the cancerous tissue upon binding of the antibody or antigen binding portion thereof to the vascular endothelial cells proximate to or within the cancerous tissue;

contacting the biological tissue sample with the antibody or antigen binding portion thereof having a label under conditions effective to permit binding of the antibody or antigen binding portion thereof to the vascular endothelial cells proximate to or within the cancerous tissue in the biological tissue sample;

detecting a presence of any cancerous tissue in the biological tissue sample by detecting the label; and

wherein the antibody or antigen binding portion thereof comprises an antigen binding portion of an amino acid sequence encoded by a nucleic acid sequence selected from the group consisting of a nucleic acid sequence which encodes the variable heavy chain produced by the hybridoma having ATCC deposit no. HB-12109, and a nucleic acid sequence which encodes the variable light chain produced by the hybridoma having ATCC deposit no. HB-12109.

26. A method according to claim 25, wherein the antibody or antigen binding portion thereof comprises an antigen binding portion of an amino acid sequence encoded by a nucleic acid which encodes the variable heavy chain produced by the hybridoma having ATCC deposit no. HB-12109 and an antigen binding portion of an amino acid sequence encoded by a nucleic acid which encodes the variable light chain produced by the hybridoma having ATCC deposit no. HB-12109.

27. A method according to claim 1, further comprising:

providing a monoclonal antibody which, when contacted with an extracellular domain of prostate specific membrane antigen, binds to the extracellular domain of prostate specific membrane antigen; and

contacting cancerous prostate epithelial cells or contacting PSMA-expressing vascular endothelial cells proximate to the cancerous cells with the monoclonal antibody under conditions effective to permit both binding of the monoclonal antibody to the cancerous prostate epithelial cells or to the PSMA-expressing vascular endothelial cells proximate to the cancerous cells and ablating or killing of the cancerous cells.

28. A method according to claim 27, wherein the monoclonal antibody or ablates the PSMA-expressing vascular endothelial cells proximate to the cancerous cells, thereby killing or ablating the cancerous cells by reducing blood flow thereto.

\* \* \* \* \*

UNITED STATES PATENT AND TRADEMARK OFFICE  
**CERTIFICATE OF CORRECTION**

PATENT NO. : 8,951,737 B2  
APPLICATION NO. : 11/939422  
DATED : February 10, 2015  
INVENTOR(S) : Neil H. Bander


Page 1 of 1

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In the Claims

In claim 28, column 46, line 52, please correct a typography as follows:  
Insert the word --kills-- between “clonal antibody” and “or”.

Signed and Sealed this  
Second Day of June, 2015

A handwritten signature in black ink, reading "Michelle K. Lee". The signature is written in a cursive, flowing style.

Michelle K. Lee  
*Director of the United States Patent and Trademark Office*

专利名称(译)	治疗和诊断癌症		
公开(公告)号	<a href="#">US8951737</a>	公开(公告)日	2015-02-10
申请号	US11/939422	申请日	2007-11-13
[标]申请(专利权)人(译)	打捆NEIL ^ h		
申请(专利权)人(译)	打捆NEIL ^ h		
当前申请(专利权)人(译)	康奈尔研究基金会，INC.		
[标]发明人	BANDER NEIL H		
发明人	BANDER, NEIL H.		
IPC分类号	G01N33/53 G01N33/574 A61K39/395 A61K39/00 A61K47/48 A61P35/00 B82Y5/00 C07K16/30 C12P21/08		
CPC分类号	A61K47/48638 A61K47/48761 B82Y5/00 C07K16/3069 G01N33/57434 A61K2039/505 C07K2317/77 G01N2333/705 A61K47/6869 A61K47/6899		
代理机构(译)	普洛思律师事务所		
代理人(译)	郑，利华		
其他公开文献	US20090238755A1		
外部链接	<a href="#">USPTO</a>		

#### 摘要(译)

使用抗体或其结合部分，探针，配体或其他生物制剂，其识别前列腺特异性膜抗原（PSMA）的细胞外结构域或结合并用PSMA内化。可以标记这些生物制剂并用于检测癌组织，特别是接近或含有血管内皮细胞的癌组织，其表达PSMA的细胞外结构域。标记的生物制剂也可用于检测正常，良性增生和癌性前列腺上皮细胞或其部分。它们还可以单独使用或与有效消融或杀死此类细胞的物质结合使用，作为前列腺或其他癌症的疗法。还公开了四种杂交瘤细胞系，每种细胞系产生识别正常，良性增生和癌性前列腺上皮细胞或其部分的PSMA细胞外结构域的单克隆抗体。




FIG. 1